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Histone lysine methyltransferases have crucial roles in a number of biological 
processes and human diseases by controlling gene expression and chromatin state. 
Within this family, the lysine methyltransferase G9a has emerged as critical player 
in several pathologic states, particularly because of its important role in the 
silencing of tumor suppressor genes and in the regulation of other chromatin events. 
The low number of G9a chemical probes suitable for cell-based and animal studies, 
as well as the limited chemical diversity demand for the development of new 
modulators. 
In this thesis, two different approaches aimed at the identification of novel 
chemotypes for the modulation of G9a are presented. On one hand, from a 
medicinal chemistry prospective, we considered the modification of the central core 
of the potent and selective inhibitor UNC0638, resulting in a 1,4-benzodiazepine 
derivative EML741. To validate the approach, we designed and synthesized a small 
set of ring-expanded derivatives and tested their activity in vitro. Peptide-based 
biochemical assays (AlphaLISA) validated our design, as compound EML741 
preserves the activity of the parent compound. In fact, EML741 is a G9a 
competitive inhibitor with respect to substrate endowed with potent activity and 
selectivity. In addition, EML741 showed favorable physico-chemical properties as 
it is quite soluble and chemical stable in aqueous media, and exhibited a membrane 
permeability profile (PAMPA and PAMPA-BBB) better than the parent compound 
UNC0638.  
The second approach was aimed to explore a high-diversity chemical space, 
generating a reporter cell line that enhance the expression of a fluorescent protein 
as result of chromatin changes provoked by G9a inhibition. By means of lentiviral 
infection, a construct encoding for a blue fluorescent protein (BFP) was integrated 
in the background of the human KBM7 cell line, in genomic loci whose chromatin 
organization is regulated by G9a activity. Two cell lines were selected and their 
specificity to detect G9a inhibition was preliminary evaluated. The validation of 
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these cell lines is still ongoing. When completed, this reporter could be used both 






















Genetic mechanisms alone cannot explain why cells of multicellular 
organisms, that have the same set of genetic instructions, become highly specialized 
to perform different functions.  
In 1942, Conrad Waddington coined the term epigenetics to define the “causal 
interactions between genes and their products which bring the phenotype into 
being”.1 The word etymologically derives from the Greek επί (epì) γεννετικός 
(genetikòs) and literally means “above or beyond genetics”. Over the years, the 
concept of epigenetic has been continuously expanded and revised.2 To date, 
epigenetics refers to all the mechanisms that work in addition to the DNA template 
to regulate and perpetuate gene expression programs and thereby canalize cell-type 
identities.3 Epigenetic modifications can be accumulated during a lifetime, but also 
transmitted to the offspring, even if mechanisms behind such heritability are often 
unclear.4 In addition to stable marks, some epigenetic modifications are highly 
flexible and easily reversed to respond to environmental stimuli.5 
 
1.2 The genome organization 
Eukaryotic cells package their genome in the form of a DNA-protein complex 
known as chromatin. Besides the packaging role, the chromatin organization allows 
a cell to fine control the accessibility of different genomic regions for transcription, 
recombination, DNA repair and replication.6 The basic packaging element of 
chromatin is the nucleosome, which consists of 146 base pairs of DNA wrapped 
around an octameric protein complex, made up of four highly basic proteins named 
histones (H2A, H2B, H3, and H4). Histones, bearing positively charged residues, 
are able to interact with the negatively charged DNA phosphate backbone (Figure 
1.1).6-7  




Figure 1.1 Structure of the nucleosome core particle. Picture adapted from 
Setiaputra, D. et al., BBA-Proteins Proteomics 2017, 1865, 1613-1622. 
 
At the molecular level, epigenetic control of gene expression involves 
covalent and reversible post-synthetic modifications of DNA and histone proteins. 
These modifications, together with non-coding RNAs (ncRNAs), histone variants 
and nucleosome remodelers, can induce changes in chromatin structure, resulting 
in transcriptional regulation without altering the underlying DNA sequence.8 In 
other terms, epigenetic modifications label specific genomic regions to recruit 
different chromatin-binding proteins, ultimately resulting in cellular 
reprogramming and response to the environment (cellular plasticity).3 
 
1.3 Histone modifications 
Since Allfrey’s pioneering studies in the mid-1960s highlighted histones post-
translational modifications (PTMs), major discoveries have uncovered their key 
role, in addition to DNA methylation, in carrying information that can distinguish 
transcriptionally active or silent chromatin states.9  
Histone PTMs include acetylation, methylation, phosphorylation, 
ubiquitinylation, sumoylation, ADP ribosylation, and deamination. These 
modifications mainly occur on the N-terminal regions (tails) of the histones, which 
protrude from the nucleosome and are accessible to the epigenetic machinery 
(Figure 1.2). Epigenetic marks can either affect the chromatin structure by merely 
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being there, but also influencing inter-nucleosomal interactions and recruiting 
remodeling enzymes, thus changing the overall chromatin architecture.10 
 
 
Figure 1.2 Post translational modifications on the histone tails. Picture 
adapted from Lawrence, M. et al., Trends Genet. 2016, 32, 42-56. 
 
Histone modifying proteins are usually categorized as writers, readers and 
erasers (Figure 1.3).11 Epigenetic writers, such as histone acetyltransferases 
(HATs), histone methyltransferases (HMTs) and kinases, catalyze the addition of 
epigenetic marks on amino acid residues on histone tails. Epigenetic readers, such 
as proteins containing bromodomains, chromodomains and Tudor domains, are 
“effector proteins” that recognize and bind to epigenetic marks, and consequently 
recruit various components of the nuclear signaling network to chromatin. Lastly, 
when epigenetic marks are no longer needed, they can be removed by epigenetic 
erasers, such as histone deacetylases (HDACs), histone demethylases (HDMs) and 
phosphatases. The complex interplay of these three classes of proteins results in a 
tight regulation of gene activity and expression during development and 
differentiation, or in response to intra- or extracellular events.7, 11  




Figure 1.3 Epigenetic writers, readers and erasers. Picture adapted from 
Falkenberg, K. J. et al., Nat. Rev. Drug Discovery 2014, 13, 673-691. 
 
1.4 Histone methylation 
Among epigenetic marks, methylation of histone proteins constitutes a highly 
complex control system directing diverse functions of the genome. Histone 
methylation state is tightly regulated by an intricate system made up by a large 
number of site-specific methylases (HMTs), demethylases (HDMs) and methyl 
reader proteins.12  
Histone methylation mainly occurs at lysine and arginine side chains. For this 
reason, HMTs are generally classified as protein Lysine Methyltransferases 
(KMTs) and protein Arginine Methyltransferases (RMTs). The number of methyl 
groups that can be incorporated into a specific residue is different and can confer 
unique transcriptional, and therefore phenotypic, effects on cells. Thus, the ε-amino 
group of lysines can be mono-, di-, or trimethylated, while the guanidine nitrogen 
of arginine residues can accommodate one (ω-NG-monomethyl arginine (MMA)) 
or two methyl groups in an asymmetric or symmetric manner (ω-NG,NG-
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asymmetric dimethyl arginine (ADMA) and ω-NG,N′G-symmetric dimethyl 
arginine (SDMA)) (Figure 1.4). According to the case, the addition of more than 
one methyl group can be carried out in a processive or distributive manner.13 
 
 
Figure 1.4 Lysine (A) and arginine (B) methylation states. 
 
The human genome encodes more than 60 PMTs including 9 known protein 
arginine methyltransferases (PRMTs) and >50 protein lysine methyltransferases 
(PKMTs).  
The catalytic mechanism is common to both families and consists of SN2 
transfer of a methyl group from the universal methyl donor S-adenosyl-L-
methionine (SAM or AdoMet) to the nitrogen atom(s) of a lysine or arginine 
residue, generating the methylated histone product and S-adenosyl-L-homocysteine 
(SAH or AdoHcy, Figure 1.5).13-14 
 




Figure 1.5 Generic SN2 methyl transfer reaction from SAM to the amino-acid 
side-chain nitrogen of a lysine/arginine residue on histones tails. 
 
Unlike other epigenetic modifications, such as acetylation or 
phosphorylation, methylation of both arginine and lysine residues does not 
neutralize or alter the amino acid charge. Therefore, the effect of chromatin 
remodeling is not due to an alteration of the electrostatic interactions between DNA 
and histone proteins. Instead, methyl marks act as recruiting sites for proteins that 
compact nucleosomes together or engage additional regulatory proteins to the 
methylation site, mediating a variety of downstream effects. Hence, each type of 
mark is a specific signal that is recognized by highly evolved methyl binding 
domains, resulting in either transcriptional activation or repression.15-16 
Additionally, it has been now widely demonstrated that arginine/lysine 
methylation also occurs on various non-histone substrates, resulting crucial for the 
regulation of their activities. Among these, there are key components of several 
cellular signaling pathways, such as nuclear factor-kappa B (NF-κB), the epidermal 
growth factor receptor (EGFR), as well as the tumor suppressor p53 or the estrogen 
receptor (ER).17-20 
Hence, a dysregulated activity of histone methylation modifiers can lead to 
altered expression patterns of oncogenes or tumor suppressor genes, as well as to 
an altered methylation state of effector proteins, thus resulting in aberrant cellular 
signaling cascades and cellular transformation.17 Therefore, proteins governing this 
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modification are of substantial interest from the perspective of medicinal chemistry 
and drug discovery.12, 15 
 
1.5 Protein lysine methyltransferases (PKMTs) 
In 2000, Jenuwein and co-workers reported the identification of the first 
histone lysine methyltransferase. Since then, many other relevant discoveries, 
together with technological advances, have deeply elucidated the biological 
importance of histone lysine methylation, and, therefore, of proteins governing this 
modification.21  
With the exception of DOT1L (Disruptor of telomeric silencing 1-like), the 
catalytic activity of lysine methyltransferases is located in an approximately 130 
amino acid-long conserved domain called the SET domain. The SET domain was 
first recognized as a conserved sequence in three Drosophila melanogaster 
proteins: a modifier of position-effect variegation, Su(var.)3−9 (the suppressor of 
position-effect variegation 3−9),22 the Polycomb-group chromatin regulator 
En(zeste) (Enhancer of zeste),23 and the homeotic gene regulator Trithorax.24 
Differently from other SAM-dependent enzymes, in SET domain-containing 
proteins the binding sites for the histone substrate and the cofactor are located on 
opposite sides of the domain and are connected through a deep channel. It has been 
proposed that this particular arrangement consent the processive methylation lysine 
residues.25 
Besides this common feature, SET domain KMTs display low sequence 
similarity and the residues at the active site are not all conserved, thus explaining 
their high substrate specificities.26 Moreover, these enzymes exhibit a different 
product specificity, defined as the number of methyl group transferred to the 
substrate (Figure 1.6).27 Importantly, have been recently identified many other SET 
domain-containing proteins that exclusively methylate non-histone substrates and 
do not appear to target histones directly. Moreover, in many proteins the SET 
domain co-occurs with multiple other domains.28 
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Histone lysine methylation mainly arises on histones H3 and H4. In 
particular, five lysine residues are located on H3/H4 tails, while one site of 
methylation is placed on H3 globular core.16 Lysine methylation has been 
implicated in both transcriptional activation (H3K4, H3K36, H3K79) and silencing 
(H3K9, H3K27, H4K20). Apart from the residue modified, also the degree of 
methylation is responsible of the different outcomes.29 
 
 
Figure 1.6 Phylogenetic tree of KMTs. Picture modified from Milite, C. et 
al., Clinical Epigenetics 2016, 8, 1-15. 
 
1.6 KMTs in health and disease 
In the wide scenario of histone modifications, lysine methylation has 
attracted increasing attention because of its crucial regulatory role in important 
nuclear processes including transcription, cell cycle control and DNA damage 
response.30-32 The physiological roles and the links to disease states of this 
epigenetic mark will be examined below.  
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1.6.1 The physiological role of KMTs 
The number of targetable histone lysine residues and the degree of 
methylation on each methylation site generate an extremely complex collection of 
potential functional outputs. This picture is actually even more complex, because 
histone methylation marks exert their activity cooperatively with other types of 
histone modifications (epigenetic cross-talk).33 
Repressive methylation marks (H3K9, H3K27, H4K20) are essential for the 
X chromosome inactivation process,34 transcriptional silencing of euchromatic 
genes,35 as well as for the establishment and maintenance of highly condensed 
(heterochromatic) regions, such as centromeres.36 
Instead, transcriptionally competent euchromatin is characterized by 
methylation on different residues, e.g. H3K4, H3K36 and H3K79. At chromosome 
level, specific histone methylation marks accomplish the establishment of 
permissive euchromatin by preventing silencing mechanisms to be carried out, such 
as binding of repressive complex or deposition of silencing marks. Furthermore, at 
gene level, lysine methylation is associated with the transition from transcription 
initiation to productive elongation stage.32, 37 
Moreover, lysine methylation is important for the regulation of early steps in 
the replication processes,38 as well as in DNA damage response.39 
The biological importance of lysine modifying enzymes is even greater 
considering as their role in the regulation a number of non-histone proteins has a 
wide-ranging impact over a growing amount of cellular processes and disease 
states. Mono-, di- or trimethylation of non-histone substrates can positively or 
negatively affect protein stability, influence protein-protein interaction or, in some 
cases, subcellular localization.20 In addition, again the crosstalk with other PTMs 
has to be taken into account. For example, one of the most studied non-histone 
protein that is regulated by lysine methylation is the well-known tumor suppressor 
p53. This protein bears at least four distinct lysine methylation sites in the C-
terminal region (K370, K372, K373 and K382). Both the position of the methylated 
lysine residues and the methylation state (e.g., mono- or dimethylation) influence 
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p53 activity, allowing the fine-tuning of p53 functions in homeostatic conditions or 
stress responses.40  
 
1.6.2 The pathological role of KMTs 
Is now clear that dynamic chromatin modifications are a mean by which cells 
establish the appropriate epigenetic homeostasis. Thus, the importance of the fine 
regulation of histone methylation is continuously evidenced by emerging links 
between histone methylation and disease states or ageing.41-43 In fact, a growing 
amount of evidences indicates that the alteration of global histone methylation as 
well as the loss or gain of specific methyl marks have a role in a number of 
cancers, correlating with tumor phenotype, patient outcome and prognostic 
factors.44-46 For example, the H3K27me3 methyltransferase EZH2 is up-regulated 
in a number of cancers, including breast and prostate cancer.47 In the same way, 
activating point mutations in EZH2 have recently been identified and are associated 
with B cell lymphomas.48 On the other hand, mutations that cause a loss of 
methyltransferase activity of EZH2 have been recognized in myelodysplastic 
syndromes, supporting the view that EZH2 functions as a tumor suppressor in that 
cancer type.49 
Another noteworthy example of a histone methyltransferase involved in 
tumorigenesis is the H3K4 methyltransferase MLL1 (Mixed-Lineage Leukaemia 1). 
Thus, the MLL (also known as ALL‑1 and KMT2A) gene rearrangement is one of 
the most common chromosomal abnormalities in human leukaemia, resulting 
mutated in almost 80% of infant leukaemia and 5-10% of adult acute myeloid and 
lymphoid leukaemia.50 
Dysregulation of histone methylation is also implicated in a number of 
neurodevelopmental disorders, including intellectual disabilities, autism, 
schizophrenia, and other conditions of importance, for instance Huntington’s 
disease.51-54  
Introduction   
12 
 
Furthermore, aberrant activity of lysine modifying enzymes is associated with 
inflammation55 and autoimmune diseases,56 cardiovascular diseases57-58 and 
diabetes complications.59 
 
1.7 Euchromatin histone methyltransferase 2: G9a 
The Euchromatin Histone Methyltransferases (EHMTs) are a subfamily of 
KMTs responsible of mono- and dimethylation of lysine 9 on histone H3 
(H3K9me1, H3K9me2). In mammals, there are two EHMT proteins: G9a, encoded 
by EHMT2, and GLP (G9a-like protein), encoded by EHMT1. The name comes 
from the fact that H3K9me2 is frequently associated with repression of genes 
located in euchromatic regions. 
EHMTs G9a and GLP share 80% sequence identity in their respective SET 
domains. They are characterized by the presence of an N-terminal SET and Pre-
SET domain, preceded by a series of ankyrin (ANK) repeats, that serve as 
methyllysine binding module (protein-protein interaction).60-61  
Initial studies showed that in vivo G9a and GLP form a stoichiometric 
heteromeric complex, via their SET domain, cooperatively carrying out H3K9 
methyltransferase function.62 Nevertheless, further surveys revealed that G9a and 
GLP have different pathophysiological functions, also displaying distinct tissue-
specific expression profiles.61, 63-64 Moreover, transcriptomic analysis shows that 
these two proteins regulate different sets of genes.65 
 
1.7.1 The physiological role of G9a 
As mentioned above, G9a (EHMT2 or KMT1C) catalyze mono- and 
dimethylation of lysine 9 of histone H3 and, to a lesser extent, monomethylation of 
lysine 27 of histone H3 (H3K27me1). In particular, two residues of tyrosine are of 
essential for the catalytic activity (Tyr1154) and H3K9 substrate specificity 
(Tyr1067).66 Moreover, recently G9a was reported as the enzyme responsible of the 
monomethylation of the lysine 56 of histone 3 (H3K56me1). This mark serves as 
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chromatin docking site for the replication processivity factor PCNA, preceding its 
function in DNA replication.67 
During the development, G9a is ubiquitously expressed in all cell types and 
carries out important functions in the biological processes associated with gene 
regulation, including embryogenesis,68 germ cell development,69 immune 
response,70 neural development and brain function.71-72 At a molecular level, G9a 
is essential for transcriptional repression,73-74 gene imprinting,75 provirus 
silencing,76 and DNA methylation.76-78  
Almost all these functions are dependent on H3K9 methylation, nevertheless, 
like other methyltransferases, G9a methylates also a plethora of non-histone 
targets.79-80 The first identified non-histone substrate of G9a was G9a itself: 
autocatalytic G9a methylation recruits the epigenetic regulator heterochromatin 
protein 1 (HP1), thus enhancing the silencing of gene transcription.81 Among G9a 
non-histone substrates, there are several transcription factors, whose methylation 
usually results in their inactivation and consequent silencing of the target genes.82-
83 Of note, dimethylation of lysine 373 by G9a/GLP maintains the transcription 
factor p53 in an inactive state, thus inhibiting its function as tumor-suppressor.84 
 
1.7.2 The pathological role of G9a 
As mentioned above, mutations in the epigenetic machinery and the resulting 
altered placement of epigenetic marks are frequently involved in various 
pathological conditions. Therefore, a deep understanding of epigenetic phenomena 
and their alterations in diseases has become a priority in biomedical research, 
especially because, unlike genetic alterations, epigenetic aberrations are reversible. 
15, 85 
In the past years, numerous studies have provided evidences that link an 
aberrant activity of G9a to human diseases. Primarily, G9a is overexpressed in 
various human cancers, including leukaemia,86-87 prostate carcinoma,84 
hepatocellular carcinoma88 and lung cancer.89  
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Moreover, G9a plays a role in neurodegeneration induced by either ethanol 
and cocaine addiction,90-91 mental retardation,92-93 inflammatory diseases94-95 and 
maintenance of HIV-1 (Human Immunodeficiency Virus type 1) latency.96 
 
1.7.2.1 A specific role for G9a in medulloblastoma (MB)  
Of particular interest, a recent work by the group of Prof. Vidya 
Gopalakrishnan (University of Texas, MD Anderson Cancer Center, Houston, 
Texas) in collaboration with our research group, proved the role of G9a in human 
medulloblastoma (MB).97 MB is the most malignant pediatric brain tumor, also 
named cerebellar primitive neuroectodermal tumor (PNET) because it origins in a 
region of the brain at the base of the skull, called the posterior fossa. Unlike most 
brain tumors, MB rapidly metastasizes via the cerebrospinal fluid.98 To date, it is 
still a leading cause of cancer-related deaths in children. Current therapy is not 
specific for this tumor, basically relying on chemotherapy, craniospinal irradiation 
and surgery. More importantly, whilst the number of survivors after diagnosis and 
treatment is growing, the well-documented poor quality of that survivorship has 
extended the concept of cure to include improvements of long-term cognitive 
outcome.99-100 The aforementioned study pointed out that G9a inhibition has the 
potential for therapeutic applications in MB. In fact, previous works had shown that 
the RE1 Silencing Transcription Factor (REST) signaling pathway was aberrantly 
activated in over 80% of MBs and associated with poor prognostic significance in 
patients.101 REST-dependent maintenance of tumor cell proliferation is mediated 
by an ubiquitin-specific protease (USP), USP37, that is downregulated in high-
REST expressing MBs as result of REST aberrant activity. USP37 is essential for 
the stabilization of the cyclin-dependent kinase inhibitor (CDKI), p27. The failure 
to stabilize p27 directly endorse deregulated cell proliferation.102 USP37 silencing 
is mediated by a significative increase of level of trimethylation of histone H3K9 at 
USP37 promoter, a mark deposited by G9a following REST recruitment. It has been 
demonstrated that inhibition of G9a activity by means of small-molecules restores 
USP37 expression and its tumor-suppressive activity, resulting in medulloblastoma 
growth arrest in mouse orthotopic models (Figure 1.7).  





Figure 1.7 Model to summarize the effect of G9a inhibition on USP37 gene 
expression. A, REST binds to a RE1-binding site on the USP37 promoter and 
recruits G9a that catalyze di- and trimethylation of histone H3K9, resulting in gene 
silencing; B, G9a inhibition by means of small-molecule reestablishes USP37 
expression. Picture modified from Dobson, T. et al., Mol Cancer Res 2017, 15, 
1073-1084. 
 
1.8 G9a as relevant drug target 
Given the role of G9a in diverse biological processes, the development of 
specific G9a inhibitors has been increasingly pursued over the years and is currently 
the focus of many research groups.103 
G9a inhibitors so far described in literature are usually categorized in two 
classes: molecules belonging to the Class I bind to the substrate pocket while Class 
II inhibitors are binders of the SAM pocket. In the following sections, these two 
classes will be briefly reviewed.  
 
1.8.1 Binders of the SAM pocket (Class II) 
A small number of compounds bears to the Class II inhibitors. In fact, there 
has been restricted focus on developing SAM competitive inhibitors because of the 
intrinsic limit of these compounds to be able to bind others SAM-dependent 
enzymes.  
The first inhibitor of the class is a member in an epidithiodiketopiperazine 
(ETP) family of alkaloids, named chaetocin (Figure 1.8). Originally, chaetocin was 
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reported as the first inhibitor of a lysine-specific histone methyltransferase and 
specific for the methyltransferase SU(VAR)3−9 both in vitro and in vivo.104 
Some years later, Iwasa et al. published the first total synthesis of natural (+)-
chaetocin and its enantiomer and reported that both compounds effectively 
inhibited G9a (IC50 = 2.5 and 1.7 μM, respectively).
105 Subsequently, simplified 
analogues of chaetocin have also been reported, such as PS-ETP-1 (Figure 1.8).106 
Nevertheless, the low selectivity, together with the hypothesized covalent 
mechanism of inhibition,107 support the view that chaetocin and its related 
compounds are not suitable for investigating biological functions of G9a.  
 
 
Figure 1.8 Class II G9a inhibitors: Chaetocin and a simplified analogue. 
 
In 2012, Yuan and co-workers reported the discovery of BRD9539 (Figure 
1.9) by synthesizing a focused library of 2-substituted benzimidazoles inspired by 
the isoform selectivity exhibited by certain inhibitors of kinases and histone 
deacetylases.108 BRD9539 inhibits G9a with an IC50 of 6.3 μM, while no data were 
reported for GLP. Moreover, they also described the methyl ester BRD4770 (Figure 
1.9) as “pro-drug” form of BRD9539 for cell-based assays.  
 
 
Figure 1.9 Class II G9a inhibitors: Benzimidazoles. 
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The last subgroup of Class II inhibitors consists of sinefungin analogues 
(Figure 1.10). Sinefungin is a natural product, isolated from Streptomyces 
incamatus and S. griseolus, structurally closely related to SAM (it has an amino 
methylene group instead of the methylated sulfonium group) and known as broad-
spectrum “pan” methyltransferase inhibitor.109-111 Some cycloalkane sinefungin 
analogues are able to inhibit both G9a and GLP at micromolar potency, also 
effecting on three other methyltransferases (DNMT1, PRMT1 and SET7/9).112-113 
The effect on other methyltransferases was not evaluated.  
 
 
Figure 1.10 Class II G9a inhibitors: Sinefungin and its analogues. 
 
1.8.2 Binders of the substrate pocket (Class I) 
In 2007, Kubicek and co-workers identified, by a high-throughput screening 
(HTS) campaign, the first selective small-molecule inhibitor of G9a and GLP, 
BIX01294, and it was considered a major advancement in the PKMT inhibitor field 
(Figure 1.11 A).114 In fact, BIX01294 was the first inhibitor with an interesting 
potency in vitro (IC50 of 1.7 µM towards G9a and 38 µM towards GLP), combined 
with a good selectivity profile against several HMTs (up to 45 µM). Importantly, it 
was non-competitive for the cofactor and was also able in reducing H3K9me2 
levels in vivo. In their study, the inhibition of GLP by BIX01294 was measured 
under oversaturated reaction conditions, where almost all the substrate was 
converted into the trimethylated product (H3K9me3). In a following study by 
Chang and co-workers, using the same linear assay conditions for both G9a and 
GLP, BIX01294 resulted slightly more potent for GLP (IC50 = 0.7 μM) than for 
G9a (IC50 = 1.9 μM). Moreover, they also report the crystal structure of the GLP 
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SET domain in complex with BIX01294 and SAH (PDB code 3FPD), which 
confirm that the inhibitor binds to the substrate binding groove.115 
The main drawback of BIX01294 was the low activity-toxicity ratio in cells, 
that limited its use as chemical probe. Using BIX01294 as lead compound, Liu et 
al. extensively explored multiple regions of the quinazoline core, discovering, in 
2009, a derivative named UNC0224 (Figure 1.11 A),116 which was markedly more 
potent in several biochemical and biophysical assays (IC50= 15 nM). In fact, the 7-
dimethylaminopropoxy chain of UNC0224 interacts with the lysine binding 
channel, strongly increasing the potency. Focused efforts of  structure-based design 
led to the identification of E67117, E72,117 UNC0321118 and UNC0646 (Figure 1.11 
A).119 Despite the strongly improved G9a enzymatic inhibition profile (IC50 in the 
low nM range), these molecules suffer of a poor cellular activity, mostly due to the 
relatively high polarity and consequent low cell membrane permeability.  
Further efforts, in order to improve physicochemical properties while 
preserving high in vitro potency, led to the discovery of UNC0638 (Figure 1.11 A), 
by Vedadi and co-workers, in 2011. This compound was described as the first G9a 
and GLP cellular chemical probe, characterized by balanced in vitro potency, 
aqueous solubility, and cell membrane permeability.120 UNC0638 has an excellent 
selectivity profile, resulting more than 200-fold selective for G9a and GLP over 16 
other methyltransferases and epigenetic targets and at least 100-fold selective over 
other non-epigenetic proteins. More interestingly, UNC0638 retains the good 
activity in cell-based assays, together with an excellent functional potency/toxicity 
ratio. 
Finally, another optimization attempt of this chemical series resulted in the 
discovery of UNC0642 (Figure 1.11 A), a close analogue of UNC0638, that 
similarly exhibited high in vitro potency, excellent selectivity and robust on-target 
activities, and also showed good in vivo pharmacokinetics properties in mouse 
model. Nevertheless, to date UNC0638 is the most used G9a chemical probe both 
in biological and pharmacological studies.97, 121-126 
Despite scientific advancements, these remarkable efforts in improving 
quinazoline derivatives have not been combined with the identification of new 
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valuable scaffolds as G9a inhibitors. Besides the bioisosteric replacement of the 
central quinazoline ring of with a quinoline one (Figure 1.11 B),127-128 only the 
spiro(cyclobutane-1,3′-indol)-2′-amine derivative A366 (Figure 1.11 C) shares the 
same potency and mechanism of inhibition of the BIX-derivatives, despite its low 
structure similarity.129 However, this scaffold was not further developed and also 
any structural modification described in the same paper led to substantial decrease 
in potency.129 Furthermore, A366 has recently been reported as inhibitor of the 
epigenetic reader protein Spindlin1-H3K4me3 interaction and also in this case even 
minor structural modifications of A366 entail activity reduction.130 These data hang 
a question mark over A366 reliability as valuable lead compound. 
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As described in Paragraph 1.8, several G9a/GLP inhibitors have been 
identified over the last few years. Nevertheless, the number of compounds that 
meets the requisite of a good chemical probe is very low.103, 131 
Above all, the chemical diversity of current available G9a inhibitors is 
extremely limited. A successful drug discovery strategy relies on the optimization 
of a large number of variables ranging from strictly physicochemical parameters 
(e.g.  solubility, hydrogen bonding, logP), to more complex factors, for instance 
related to toxicity and bioavailability among others.132 Therefore, it is essential to 
start with a broad set of promising leads in order to identify drug candidates with 
the desired properties. 
In this regard, my PhD project was aimed to identify novel chemical entities 
endowed with good affinity towards G9a by means of two different approaches, the 
first relying basically on a medicinal chemistry perspective and the second on a 
biological one. The latter was performed at the Research Center of Molecular 
Medicine (CEMM), in Vienna, during a 6-month period abroad entailed by my PhD 
Program.  
 
2.1 Scaffold-repositioning approach  
A common medicinal chemistry strategy for discovering structurally novel 
chemotypes is the modification of the central core structure of a known active 
compound, while conserving key substituents.133-134 A change of the central 
chemical template is often a means to overcome any undesirable property 
associated with the parent molecule (e.g., potency plateau, selectivity, 
pharmacokinetics, etc.). This approach resembles the principles of the so-called 
scaffold hopping. Commonly, the concept of scaffold hopping has consistently been 
linked to computational methods and virtual screening,135 nevertheless meaningful 
scaffold replacements have been accomplished on the basis of chemical knowledge 
and intuition.133 
Therefore, pursuing our efforts toward the identification of potent and 
selective histone lysine methyltransferases inhibitors, we chose the well-validated 
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chemical probe UNC0638 as lead compound and replaced the quinazoline moiety 
with a benzodiazepine framework (Figure 2.1). In particular, the insertion of a 
methylene unit into the quinazoline ring resulted in the ring-expanded 1,4-
benzodiazepine derivative (EML741). It is worthwhile noting that the chemistry of 
the 3H-benzo[e][1,4]diazepine scaffold, which could be considered a “privileged 
structure motif”,136 had been only rarely investigated and, to best of our knowledge, 
never exploited in medicinal chemistry.  
 
Figure 2.1 Scaffold-repositioning hypothesis. 
 
Before synthesis and screening, in silico pre-evaluation of our scaffold-
repositioning hypothesis was performed in collaboration with Prof. Sandro 
Cosconati (DiSTABiF, University of Campania “Luigi Vanvitelli”, Caserta, Italy). 
 
2.1.1 Molecular Modeling Studies 
EML741 was docked (AutoDock4)137-138 into the structure of G9a to see 
whether it is able to recapitulate the interactions established by its parent compound 
(UNC0638) into the protein binding cavity (PDB code 3K5K). The docking study 
shows that, in principle, EML741 is able to recapitulate the binding mode observed 
for UNC0638 at the G9a active site (PDB code 3RJW) and, in particular, the central 
1,4-benzodiazepine scaffold may occupy the so-called “peptide binding groove”, 
establishing a number of favorable hydrophobic interactions with the side chains of 
Leu1086, Ile1161, and Ala1077, with the cyclohexyl group pointing towards a 
negatively charged region (Asp1074 and Asp1078). The secondary amino group at 
the 4-position establishes a charged-reinforced H-bond with Asp1083. This 
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interaction is known to play a crucial role in increasing the inhibitory potency.120 In 
addition, the aminoalkoxy moiety may fit into the lysine binding channel forming 
a H-bond with the backbone of Leu1086 and cation-π interactions with the aromatic 
side chains of Phe1087, Phe1152  and Tyr1154 (Figure 2.2). 
 
 
Figure 2.2 EML741 docked conformation (pink) in G9a active site (green, 
PDB 3K5K). Important residues are labeled. H-bonds are shown in grey dashed 
lines.  
 
These data are in agreement with those obtained with the recent published 
structure of G9a SET-domain PDB code 5VSE.139 The Figure 2.3 A shows the 
G9a/EML741 complex, while the superimposition of cocrystal ligand UNC0638 
(pink) and EML741 docked conformation (green) is depicted in panel B.  
 
 




Figure 2.3 A, Superimposition of cocrystal ligand UNC0638 (pink) and 
EML741 docked conformation (green) in G9a active site (orange, PDB 5VSE). B, 
G9a/EML741 complex. Important residues are labeled. H-bonds are shown in blue 
dashed lines.  
 
2.1.2 Ring-expanded 1,4-benzodiazepine derivatives 
Encouraged by the molecular modeling results, to validate the scaffold-
repositioning hypothesis and to obtain early structure-activity relationships, we 
designed a small set of ring-expanded 1,4-benzodiazepine derivatives (Figure 2.4). 
In particular, the cyclohexyl moiety of EML741 was replaced by a phenyl group 
(EML693), and to assess the importance of the central core geometry, 1,2-dihydro 
analogues were also considered (EML698 and EML696).  
 




Figure 2.4 Ring-expanded 1,4-benzodiazepine derivatives designed. 
 
2.2 A cellular reporter for functional G9a inhibition 
Systems cell biology has opened up the opportunity to study individual 
molecular targets in the context of their signaling and functional networks, giving 
the possibility of highlighting unknown links between molecular targets and 
disease. Advances in imaging technologies, as well as automated data processing 
and analysis, facilitated the implementation of biology approaches within HTS 
platforms.140 In particular, the screening of libraries of small molecules, peptides or 
RNAi aimed to the identification of those that are able to modify the phenotype of 
a cell in a desired manner (High Content Screening, HCS) is a powerful tool for the 
modern drug discovery. In the past few years, the use of HCS increased in several 
stages of the drug discovery pipeline. Indeed, of the 22 drugs approved by the FDA 
(U.S. Food & Drug Administration) in 2016, 6 have been identified using HCS.141 
The introduction of a DNA construct into a cell or an organism encoding, for 
example, for fluorescent or luminescent proteins (reporter gene) is widely used to 
monitor the cellular events associated with signal transduction and gene expression, 
both at the transcriptional or translational level.142-143 In the contest of HCS, 
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fluorescent reporters can be a valuable tool to look for small molecules that alter 
gene expression patterns in a non-invasive manner, as the fluorescent signal can be 
real-time monitored. 
For these reasons, we decided to establish a reporter cell line for the detection 
of G9a inhibition. Thus, I planned to spend my period abroad at the Research Center 
of Molecular Medicine of the Austrian Academy of Science, in the group of Dr. 
Stefan Kubicek, to learn the know-how and develop a cellular reporter able to 
activate the expression of a fluorescent marker following the chromatin remodeling 
induced by G9a inhibition (Figure 2.5). 
 
 
Figure 2.5 Experimental model and applications. 
 
In fact, as proven by Kubicek and co-workers with their reporter cell line for 
BRD4 inhibitors,144 this type of system consents the high throughput screening of 
small molecule libraries in order to identify novel and diverse G9a direct or 
functional inhibitors. The new hits, with already good ability to inhibit G9a in cells, 
could then be further optimized providing novel lead compounds. Furthermore, 
performing genome-wide genetic screening, such cell line could allow the 
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3.1 Optimization of the synthetic route to 1,4-benzodiazepin-5-ones 
The retrosynthetic analysis for the preparation of the target compounds 
(Paragraph 2.1.2) leads to a 3,4-dihydro-5H-benzo[e][1,4]diazepin-5-one scaffold 
(II), depicted in Scheme 3.1.  
 
Scheme 3.1 General retrosynthesis of target compounds. 
 
Despite the large number of publications describing the preparation of 
variously decorated benzodiazepine scaffolds, the synthesis of the 3,4-dihydro-5H-
benzo[e][1,4]diazepin-5-one nucleus has been only rarely explored. The most 
relevant synthetic strategies for the preparation of this isomer were based on the 
ring closure of properly substituted keto-anthranilamides (IV, Scheme 3.2), which 
can be obtained by reduction of the corresponding nitro derivatives (V)145-147 or 
through the reaction of an isatoic anhydride (VI) with proper α-aminoketones 
(VII).148-149  
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However, these procedures suffer the formation of undesired byproducts 
and/or are characterized by low to moderate yields. Moreover, the need for costly 
and time-consuming purification procedures makes these approaches inadequate to 
be run on larger scale, as necessary for the preparation of a key scaffold for a new 
library. For these reasons, we decided to optimize the synthesis of the 3,4-dihydro-
5H-benzo[e][1,4]diazepin-5-one scaffold based on the reduction and simultaneous 
cyclization of the corresponding 2-nitrobenzamide (Scheme 3.3). We studied the 
proposed reaction using three model substrates, choosing as substituents phenyl- 
and cyclohexyl-, that would be used for the preparation of the designed compounds, 
and another less sterically hindered aliphatic substituent (isopropyl-) to further 
verify the robustness and versatility of the method.  
 
Scheme 3.3 Reaction model. 
 
3.1.1 Preparation of 2-nitrobenzamides 2a-c 
The 2-nitrobenzamides 2a-c were obtained by condensation of 4-
(benzyloxy)-5-methoxy-2-nitrobenzoic acid (3) with properly substituted α-
aminoketones (Scheme 3.4). The synthesis of these derivatives will be illustrated 
below.  
 
Scheme 3.4 General synthetic strategy for nitrobenzamides 2a-c. 
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3.1.1.1 Synthesis of 4-(benzyloxy)-5-methoxy-2-nitrobenzoic acid (3) 
The synthetic strategy for the preparation of 4-(benzyloxy)-5-methoxy-2-
nitrobenzoic acid (3) is depicted in Scheme 3.5.  
Vanillic acid (5) was converted into the corresponding ethyl ester derivative 
6 using a classic Fischer esterification. Subsequent benzylation using benzyl 
bromide and potassium carbonate, followed by regio-specific nitration, provided 
the 2-nitrobenzoate derivative (8) in good yield. The ethyl ester 8 was then 
hydrolyzed using an aqueous sodium hydroxide solution in THF to afford the 4-
(benzyloxy)-5-methoxy-2-nitrobenzoic acid (3). 
 
Scheme 3.5 Reagents and conditions: a) H2SO4, EtOH, reflux, 8 h (99%); b) 
benzyl bromide, K2CO3, DMF, r.t., overnight (90%); c) HNO3, Ac2O, 0 °C to r.t., 
overnight (92%); d) NaOH, THF/H2O, r.t. (98%). 
 
3.1.1.2 Synthesis of α-aminoketones 4a-c 
The 2-amino-1-phenylethan-1-one (4a) was conveniently prepared starting 
from the 2-bromoacetophenone (9). The bromine was replaced by azide (10) that 
was subsequently reduced via Staudinger procedure, in presence of hydrochloric 
acid, to afford the desired product (4a) (Scheme 3.6).  
 
Scheme 3.6 Reagents and conditions a) sodium azide, DMF, 0 °C, 30 min 
(98%), b) triphenylphosphine, MeOH, 37% HCl, 0 °C to r.t., overnight (quant.). 
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A different procedure was used for the preparation of the α-aminoketones 4b 
and 4c (Scheme 3.7). The Weinreb amide 12 was prepared starting from Boc-
glycine (11), which was subjected to amide coupling with N,O-
dimethylhydroxylamine under mild conditions using carbonyl diimidazole (CDI). 
Addition of the proper Grignard reagent to 12 afforded the corresponding N-Boc 
protected derivatives 13b and 13c, which were straightforwardly converted into the 
corresponding α-aminoketones 4b and 4c by treatment with trifluoracetic acid in 
dichloromethane. 
.  
Scheme 3.7 Reagents and conditions: a) N,O-dimethylhydroxylamine 
hydrochloride, CDI, triethylamine, dry THF, 0 °C to r.t., overnight (80%) b) 
cyclohexylmagnesium chloride (or isopropylmagnesium chloride), dry THF, -15 
°C 1 h, then r.t. 1 h (45-50%) c) DCM/TFA 1:1, r.t. 2 h (quant.). 
 
3.1.1.3 Coupling reaction 
Finally, as reported in Scheme 3.8, the 2-nitrobenzamides 2a-c were prepared 
in good yields by treating 4-(benzyloxy)-5-methoxy-2-nitrobenzoic acid 3 with 
proper α-aminoketones 4a-c, using HOBt and HBTU as amide-coupling reagents. 
 
Scheme 3.8 Reagents and conditions: a) HOBt, HBTU, DIPEA, dry 
THF/DMF 4:1, 0 °C to r.t., 12 h (70-85%). 
 
3.1.2 Exploration of batch reduction procedures 
We therefore tested and compared different reaction conditions, starting from 
the classical batch procedures, as summarized in Table 3.1. The main byproducts 
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recovered from the reduction of the 2-nitrobenzamides 2a-c are depicted in Figure 
3.1.   
The catalytic hydrogenation of the 2-nitrobenzamides always resulted in the 
cleavage of the benzyl group and yielded different byproducts depending on the 
starting compound. In particular, reduction of substrate 2a using palladium on 
carbon (10% Pd/C) afforded derivative 14a, in which the nitro- and the keto-groups 
were reduced (Table 3.1, entry 1). Instead, in the same conditions, the 
nitrobenzamide 2b afforded the tetrahydrobenzodiazepinone 15b (Table 3.1, entry 
2). For the phenyl derivative 2a, the conversion to the tetrahydrobenzodiazepinone 
15a was observed under microwave-assisted catalytic transfer hydrogenation 
conditions, using 1,4-cyclohexadiene as hydrogen donor and palladium on carbon 
as catalyst (Table 3.1, entry 3).150  
Conversely, the traditional non-catalytic reduction of the substrates with iron 
sulfate heptahydrate (Table 3.1, entries 4-6) gave the desired 3,4-dihydro-5H-
benzo[e][1,4]diazepin-5-ones 1a-c, although in moderate yields (53-61%). A slight 
yield improvement was obtained only for the phenyl derivative 1a using iron 
powder in acetic acid (Table 3.1, entry 7). Nevertheless, these conditions were 
hardly satisfactory. In fact, besides the not excellent yields, these methods suffer 
from various practical drawbacks. For example, the large excess of reagents implies 
the generation of big amounts of waste and therefore requires tedious work-up and 
time-consuming purification procedures. 
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Table 3.1 Reduction of 2-nitrobenzamides 2a-c under different batch 
conditions.a 






1 Ph H2, Pd/C A 1 h - 14a (54) 
2 c-Hex H2, Pd/C A 1 h - 15b (88) 
3 Ph 1,4-CHDN, Pd/C B 10 min - 15a (67)c 
4 Ph FeSO4/NH3 C 8 h 53 - 
5 c-Hex FeSO4/NH3 C 16 h 55 - 
6 i-Pr FeSO4/NH3 C 2 h 61 - 
7 Ph Fe/AcOH D 2 h 77 - 
8 c-Hex Fe/AcOH D 2 h 51 - 
9 i-Pr Fe/AcOH D 2 h 63 - 
aReaction conditions: A) H2, 10% Pd/C (10%, 0.1 eq.), EtOAc/EtOH 2:1 
(0.03 M), 20 °C, 1 atm; B) 1,4-cyclohexadiene (1,4-CHDN, 6 eq.), Pd/C (10%, 0.05 
eq.) MeOH (0.1 M), MW (120 °C); C) FeSO4·7H2O (10 eq.), NH4OH, EtOH, 
reflux; D) Fe (20 eq.), AcOH (0.1 M), 70 °C; bIsolated yield after chromatographic 
purification; cDebenzylated nitro compound (22%) was also recovered. 
 
3.1.3 Optimization of flow reaction conditions 
Thus, following our interest in exploiting modern synthetic technologies to 
improve classical organic reactions,151 we considered the possibility to further study 
this reaction taking advantage of the continuous-flow technology. Usually flow-
chemistry exhibits a number of potential advantages. Above all, it allows a tight 
control of the reaction variables, an increased safety, the possibility of run reactions 
at high temperature and pressure (process intensification), reduced manual handling 
and higher reproducibility, easier scale-up and many others.152  
To perform our study, we made use of the hydrogenation reactor H-Cube 
Pro™ (Thales Nanotechnology Inc., Figure 3.2). This reactor allows the user to work 
in totally safe conditions, since the hydrogen is generated inside the instrument by 
the electrolysis of water and the catalysts are packaged in cartridges. Moreover, the 
fast and easy change of the catalyst cartridge and/or of various reaction parameters 
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(temperature, pressure and flow rate) consent the easy set-up of a wide range of 
experimental conditions.  
 
 
Figure 3.2 H-Cube Pro™ (Thales Nanotechnology Inc.). 
 
Hence, we performed a thorough screening of different catalysts and reaction 
conditions in order to identify the best ones for the reduction and concomitant 
cyclization of substrates 2. 
At first, the flow hydrogenation of 2-nitrobenzamide 2a was optimized using 
a 0.03 M solution of substrate (0.30 mmol) in EtOAc/EtOH (10 mL), 1.0 mL/min 
as flow rate, 10 bar of pressure at 30 °C in full-H2 mode. According to the results 
obtained under batch conditions, the hydrogenation of the 2-nitrobenzamide 2a 
using Pd/C as catalyst yielded only the debenzylated anilino alcohol 14a (Table 3.2, 
entry 1). The same result was observed using rhodium on carbon (5% Rh/C) as 
catalyst and 50 bar of pressure (Table 3.2, entry 2).  
Instead, the use of platinum on carbon (5% Pt/C) had a more encouraging 
outcome, since it afforded the desired benzodiazepin-5-one 1a even if in very low 
yield (12%, entry 3). The low yield was primarily due to ineffective cyclization 
step, as the main product of this reaction was the intermediate anthranylamide 16a 
(Figure 3.1). Therefore, we decided to promote the cyclization by using a more 
appropriate solvent, THF (Table 3.2, entry 4), and raising the temperature to 80 °C 
(Table 3.2, entry 5). In this case, the partial conversion negatively affected the 
yields. Subsequently, the pressure was raised to increase conversion while the flow 
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rate was slowed down to promote ring closure (Table 3.2, entry 6). Nevertheless, in 
these conditions the desired product was obtained in moderate yield (52%). 
Moreover, the cyclization was still incomplete and the 1,2-dihydro-derivative 17a 
(Figure 3.1) was also recovered as main byproduct.  
Finally, we resolved to switch to ruthenium, an uncommon metal in 
heterogeneous catalysis, but reported to be selective for preferential hydrogenation 
of aromatic nitro groups.153 To our pleasure, using the improved reaction conditions 
disclosed (THF as solvent, 0.3 mL/min as flow rate and 50 bar of pressure at 80 °C) 
the reaction gave exclusively the desired 3,4-dihydro-5H-benzo[e][1,4]diazepin-5-
one 1a in excellent 94% yield and without the need for further purification, as the 
yield did not significatively change after chromatographic purification (entry 7). 
Applying this the procedure also to the substrates 2b and 2c, the corresponding 
products 1b and 1c were obtained in comparable excellent yields (entries 8 and 9). 
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Table 3.2 Reduction of 2-nitrobenzamides 2 under continuous-flow conditions.a 














1 Ph 10% Pd/C 30 
EtOAc/EtOH 
2:1 
1.0 10 >99 - 14a (>98) 
2 Ph 5% Rh/C 30 
EtOAc/EtOH 
2:1 
1.0 50 >99 - 14a (>98) 
3 Ph 5% Pt/C 30 
EtOAc/EtOH 
2:1 
1.0 10 94 12 16a (82) 
4 Ph 5% Pt/C 30 THF 1.0 10 54 21 16a (33) 
5 Ph 5% Pt/C 80 THF 1.0 10 60 50 16a (10) 
6 Ph 5% Pt/C 80 THF 0.3 50 >99 52 16a (18) + 17a (25) 
7 Ph 5% Ru/C 80 THF 0.3 50 >99 94 (93)c - 
8 i-Pr 5% Ru/C 80 THF 0.3 50 >99 94 (92)c - 
9 c-Hex 5% Ru/C 80 THF 0.3 50 >99 92 (91)c - 
aH-Cube ProTM, Full-H2 mode, 30 mm × 4 mm i.d. catalyst cartridge,  150 mg of catalyst; 
bCalculated as 100 − % of residual 
nitroderivative 2 as determined by HPLC; cDetermined by HPLC; dIsolated yield after chromatographic purification.
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In order to more accurately compare the results obtained with the continuous 
flow hydrogenation protocol to the traditional batch conditions, we took a step back 
and performed the catalytic hydrogenation of the derivative 2a using ruthenium on 
carbon as catalyst in batch. As reported in Table 3.3 (entries 1 and 2), using the 
same molar substrate-to-catalyst ratio used in the continuous flow protocol, no 
reduction was observed at room temperature or even at higher temperature. The 
same result was obtained doubling the molar catalyst-to-substrate ratio (entry 3).  
 
Table 3.3 Reduction of 2-nitrobenzamide 2a using ruthenium as catalyst in 
batch conditions.a 





1 Ph H2, Ru/C E 18 h - 2a (98) 
2 Ph H2, Ru/C F 10 h - 2a (95) 
3 Ph H2, Ru/C G 18 h - 2a (98) 
aReaction conditions: E) H2, Ru/C (5%, 0.02 eq), THF (0.03 M), 20 °C, 1 
atm; F) H2, Ru/C (5%, 0.02 eq), THF (0.03 M), reflux, 1 atm; G) H2, Ru/C (5%, 
0.04 eq.), THF (0.03 M), 20 °C, 1 atm.  
 
Finally, we evaluated the efficiency of this protocol on gram scale synthesis, 
by applying the same reaction conditions to obtain 1.3 g of compound 1a. The 
amounts of substrate and solvent were proportionally scaled. Also in this case, the 
desired product was isolated with high purity and in excellent yield, without the 
need of multiple operator intervention. Of note, after a gram scale single run the 
conversion and the yield of the reaction were the same obtained with a new one, 
therefore proving the long-lasting efficiency of the cartridge. 
 
3.2 Functionalization of the central core 
Having obtained a robust and very efficient method for the preparation of the 
central core, we proceeded to its functionalization to obtain the designed 
compounds (Chapter 2). The synthetic strategy for the functionalization of the 
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central core is showed in Scheme 3.9. After the removal of the benzyl group from 
1a and 1b by treatment with trifluoracetic acid, the resulting unprotected derivatives 
18a and 18b were alkylated at the 8-hydroxy position with 1-chloro-3-iodopropane, 
affording the compounds 19a and 19b. Subsequently, the treatment of the 
derivatives 19 with triethyloxonium tetrafluoroborate yielded the corresponding 5-
ethoxy analogues 20a and 20b. These derivatives were reacted with pyrrolidine in 
THF, in presence of sodium iodide and potassium carbonate, furnishing the 
compounds 21a and 21b in good yields. Finally, the target compounds 22a 
(EML693) and 22b (EML741) were obtained by reaction of derivatives 21a and 
21b with 1-isopropylpiperidin-4-amine in i-PrOH, under microwave-assisted 
conditions.  
The dihydro-analogues 26a (EML696) and 26b (EML698) were prepared by 
means of a slightly modified procedure (Scheme 3.9). The reduction of the imine 
group was achieved by treatment of compounds 18a and 18b with sodium 
borohydride, affording the reduced derivatives 15a and 15b, in high yields. Once 
again, the 8-hydroxy group was alkylated with 1-chloro-3-iodopropane, but 
unfortunately, any attempt to convert the chloropropoxy derivatives 23a and 23b 
into the corresponding 5-ethoxy-analogues with triethyloxonium tetrafluoroborate 
was unsuccessful, yielding the N-alkylated derivatives as main products. This issue 
was addressed converting compounds 23a and 23b into the corresponding thionated 
derivatives by treatment with Lawesson’s reagent and subsequent in situ alkylation 
with iodoethane to afford the corresponding 5-ethylthio-derivatives 24a and 24b. 
The pyrrolidine moiety was then introduced as previously described (compounds 
25a and 25b) and subsequently the 5-ethylthio group was substituted upon 
treatment with 1-isopropylpiperidin-4-amine, yielding the desired compounds 26a 
(EML696) and 26b (EML698). 
Compared to the others, the yield of the last step is moderate (30-31%) and 
for the derivative 22b (EML741) even unsatisfactory (<5%). For this derivative, an 
improvement was obtained by reacting 21b with 1-isopropylpiperidin-4-amine in 
acetic acid, affording the desired product in a 30% yield (Scheme 3.9).   




 Scheme 3.9 Reagents and conditions: a) DCM/TFA, 1:4, 50 °C, 4 h; b) 1-chloro-3-iodopropane, K2CO3, dry DMF, r.t., overnight; c) 
triethyloxonium tetrafluoroborate, Na2CO3, dry DCM, r.t., 15 min; d) pyrrolidine, NaI, K2CO3, dry THF, MW (80 °C, 90 min); e) 1-
isopropylpiperidin-4-amine, i-PrOH, MW (200 °C, 2 h); e’) 1-isopropylpiperidin-4-amine, AcOH, MW (120 °C, 1 h);  f) NaBH4, 
THF/MeOH, 0 °C; g) Lawesson’s reagent, dry toluene, 85 °C, 1 h then K2CO3, iodoethane, 85 °C, 2 h.  
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3.3 Exploration of alternative strategies to obtain the 3H-1,4-benzodiazepine 
nucleus 
The moderate yields of the last step of the presented synthetic route 
(Paragraph 3.2) prompted us to further explore the chemistry of the 3H-1,4-
benzodiazepine (3H-1,4-BDZ) nucleus, and, in particular, to study a synthetic 
strategy to achieve the nucleus properly substituted in position 5. 
In literature were reported few examples of the synthesis of 3H-1,4-BDZs by 
the photochemical ring expansion of 4-azidoquinolines. Sashida and co-workers 
describe the synthesis of fully unsaturated 1H- (X) and 3H-1,4-BDZs (XI) by 
photochemical ring-expansion of 4-azidoquinolines (VIII) in presence of different 
nucleophiles, via the azirine intermediate (IX), as shown in Scheme 3.10.154-157 Of 
note, they frequently experience the poor stability of the 1H-1,4-BDZ nucleus and, 
consequently, the good result of the reaction often depends on the in situ 
isomerization to 3H- derivative, in presence of sodium methoxide.  
 
Scheme 3.10 General schematic of 4-azidoquinolines photo-induced 
rearrangement. 
 
3.3.1 Irradiation sources 
In the past decades, photochemical reactions were classically carried out 
using immersion well batch reactors. The light source was typically a mercury 
pressure lamp. Although these systems have found widespread use for many 
decades, they suffer from several drawbacks, such as: 
- Intense heat generation, that require the use of cold-water cooled jackets 
to prevent thermal excitation of the substrate.  
- Broad spectral output, that can result in an inefficient energy transfer, 
because, in most of the cases, only certain wavelength ranges are relevant. 
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- The lamps usually have short lifetimes, depending on the conditions of 
use (e.g. number of on-off cycles).  
 
Recent progress in the manufacture of ultraviolet light emitting diodes (UV 
LEDs) has allowed the simple generation of very efficient energy systems for the 
near UV light, which is most suitable for photochemistry. LED systems are capable 
of outperforming traditional sources of high intensity UV light. Additionally, LED 
lamps do not generate big amounts of heat, have longer lifetimes and can be turned 
on and off as desired, which further increases their overall energy efficiency and 
practical lifetime.158 
To study the ring expansion reaction, we made use of an immersion well batch 
reactor with a medium pressure mercury (HMP) lamp (Figure 3.3 A) and, in 
addition, we assembled an UV LED-based illuminator (365 nm) with Nichia chips, 
a system already successfully employed in photo-assisted organic chemistry (Figure 
3.3 B).159  
 
 
Figure 3.3. A, HMP immersion photoreactor; B, UV LED-based irradiator 
system. 
 
To verify the suitability of this method for the preparation of our compounds, 
and in particular of EML741, we chose as model substrate the 4-azido-2-
cyclohexylquinoline 27 that was irradiated with the two light sources disclosed in 
presence of isopropyl amine as nucleophile (Scheme 3.11).  
 




Scheme 3.11 Model reaction of the photochemical ring expansion. 
 
3.3.2 Synthesis of 4-azido-7-(benzyloxy)-2-cyclohexyl-6-methoxyquinoline 
(27) 
The synthesis of the 4-azidoquinoline derivative 27 is depicted in Scheme 
3.12. The acetovanillone (29) was protected with a benzyl group and subsequently 
was nitrated with fuming nitric acid in acetic anhydride at 0 °C to afford the 
compound 31 in good yields. The nitro group was then reduced in presence of 
Fe/NH4Cl and the resulting aniline (32) was acylated with cyclohexanecarbonyl 
chloride to give N-(2-acetylphenyl)cyclohexanecarboxamide 33. The derivative 33 
was then cyclized with NaOH in 1,4-dioxane to obtain the corresponding 4-
hydroxyquinoline 34. Finally, the treatment of 34 with diphenyl phosphoryl azide 
and triethylamine in anhydrous DMF at 100 °C yielded the title compound 27.  
 
Scheme 3.12 Reagents and conditions: a) benzyl bromide, K2CO3, acetone, 
reflux, 2 h (97%); b) HNO3, Ac2O, 0 °C, 15 min (83%); c) iron, NH4Cl, EtOH/H2O 
2:1, 30 min (87%); d) cyclohexanecarbonyl chloride, DIPEA, dry THF, 0 °C to r.t., 
90 min (98%); e) NaOH, 1,4-dioxane, reflux, 24 h (80%); f) diphenyl phosphoryl 
azide, triethylamine, dry DMF, 100 °C, 1 h (73%). 
 
  Chemistry 
47 
 
3.3.3 Photochemical ring expansion of the 4-azidoquinoline 27 
Besides the irradiation sources, we tested several reaction conditions by 
changing temperature (0 °C and room temperature) or solvent (THF, 1,4-dioxane, 
methanol and ethyl acetate). Unfortunately, the desired product was never obtained 
(Scheme 3.13). 
In fact, using the HMP lamp as light source, the conversion of the starting 
material into the 1H-1,4-BDZ intermediate (35) was detected by HPLC and MS 
analysis of the crude reaction. Nevertheless, it resulted too unstable to be isolated 
or isomerized to the corresponding 3H-1,4-BDZ (28). Besides unspecific 
degradation, we observed the formation of the ring-contracted derivative 36, a side 
reaction already observed for this type of nucleus, in dependence on the reaction 
conditions.160 On the other hand, when irradiated with the UV LED system, the 
reaction exclusively afforded the 4-aminoquinoline 37, suggesting that the 
energetic input was not sufficient to enable the azirine intermediate formation.161 
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Preclinical drug research has placed an increased pressure on earlier stages of 
the discovery process, in particular on the generation of quality lead compounds, 
i.e. the molecular structures selected to undergo an optimization process to 
potentially become drug candidates.162-164 A quality lead is expected to satisfy 
specific and demanding criteria, the main ones are summarized in Table 4.1. 
 
Table 4.1 Generic criteria for a quality lead compound. 
- good activity in vitro 
- robust and straightforward synthetic route  
- facile substitutions and transformations of appendages 
- logical structure-activity relationships (SARs) 
- not a promiscuous inhibitor  
- selectivity (counterscreen/secondary screen) 
- stable under biological assays conditions 
- favourable cell permeability profile 
- good activity in cell-based assays 
- high activity/toxicity ratio 
- structure free of reactive/undesirable chemotypes 
- structure reasonably drug-like  
- favourable intellectual property (ip) position 
 
Having thoroughly explored the synthetic strategy to obtain EML741 and its 
analogues, we moved to the physico-chemical and biochemical evaluation of our 
putative G9a inhibitor to establish its worth as lead for therapeutic development. 
 
4.1 Biochemical evaluation 
The effects of the ring-expanded derivatives on the catalytic activity of the 
human recombinant G9a protein were determined by means of AlphaLISA® 
homogeneous proximity immunoassay. This type of assay allows to measure enzyme 
activity by detecting the methylation of a biotinylated histone H3 peptide using 
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streptavidin-coated donor beads and AlphaLISA® acceptor beads conjugated to an 
antibody directed against the modified substrate (for instance the dimethylated lysine 




Figure 4.1 AlphaLISA assay principle. 
 
At first, the derivatives were preliminarily screened at the fixed dose of 50 
µM. All the compounds showed an almost total inhibition at the tested dose (data 
not shown), therefore their activity was measured over a range of concentrations 
from which IC50 values were determined (Table 4.2).  
 
Table 4.2 Compounds were tested in 10-dose IC50 mode with two-fold serial 
dilutions. The results reported are the mean ± SD determined for at least two 
independent experiments. 
 
 IC50 (µM) 
EML741 0.023 ± 0.008 
EML693 1.090 ± 0.092 
EML698 0.955 ± 0.087 
EML696 2.091 ± 0.094 
UNC0638 0.025 ± 0.006 
 




Figure 4.2 IC50 curves of compounds EML741 (A), EML693 (B), EML698 
(C), EML696 (D), and UNC0638 (E). Data were analyzed using GraphPad Prism 
software (version 6.0) for curve fitting, using a sigmoidal concentration-response 
with a variable slope equation. 
 
The ring-expanded 1,4-benzodiazepine derivative EML741 showed the same 
activity of the parent compound UNC0638 (IC50 = 0.023 ± 0.008 and 0.025 ± 0.006 
µM, respectively), validating both the design strategy and the computational 
analysis. Comparing the IC50 values of the different ring-expanded derivatives, it is 
also possible t establish preliminary structure-activity relationships (SARs). In 
particular, the substitution of cyclohexyl moiety with a phenyl ring (EML693) or 
the replacement of the 3H-benzo[1,4]diazepine core with the corresponding 2,3-
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dihydro-analogue (EML698) caused an approximately 50-fold decrease in potency. 
In fact, according to the molecular modeling studies presented in Paragraph 2.1.1, 
the phenyl ring (EML693) could create unfavorable repulsive interactions with the 
Asp1074 and Asp1078 (anion-π). On the other hand, the reduction of the imino 
group, as in compound EML698, alters the geometry of the central core, thus 
possibly influencing the interactions established by the 1,4-benzodiazepine nucleus 
within the “peptide binding groove” and/or the position and therefore the 
interactions of the substituents. Moreover, these effects seemed to be additive, as 
the 2,3-dihydro-analogue bearing a phenyl group, EML696, resulted 100-fold less 
active than EML741. 
 
4.1.1 Selectivity towards other epi-enzymes 
Once both potency and preliminary SARs were established, using the same 
technique EML741 was profiled on a panel of selected in-house epigenetic 
enzymes. To have comparable data, UNC0638 was tested in the same conditions. 
EML741 displayed a good selectivity profile towards the arginine 
methyltransferases PRMT1 and PRMT3. As regard the lysine methyltransferase 
SETD8, EML741 was slightly more selective than the parent compound, giving an 
inhibition of less than 25% up to 25 µM. Finally, EML741 did not markedly affect 
the activity of KDM4A, a member of the “eraser” class that specifically remove 
methyl marks on lysine-9 and lysine-36 residues of histone H3, and of the H3K9 
acetyltransferase p300 (Figure 4.3).  
The reason for the better selectivity of EML741 towards SETD8 is currently 
unclear and could be elucidated by expanding the SARs with a larger collection of 
compounds. However, selectivity is essential for a chemical probe to unbiasedly 
investigate the biological role and disease links of the target enzyme. Moreover, in 
view of the development of a drug candidate, selectivity is an important parameter 
to optimize to avoid potential toxicities or any undesirable property due to off-target 
effects. Indeed, further experiments to evaluate EML741 effect on the G9a closely 
related protein GLP and on other epigenetic enzymes are going to be carried out. 
 




Figure 4.3 Selectivity of EML741: effect on the activity of PRMT1 and -3, 
SETD8, KDM4A and p300. DMSO was used as control. UNC0638 was tested in 
the same conditions. The results are reported as mean ± SD of at least two separate 
experiments.  
 
4.2 Kinetics Measurements and Mechanism of Inhibition 
Although both molecular modeling studies and enzymatic assays results may 
indicate that our 1,4-benzodiazepine derivatives have the same inhibition 
mechanisms of the quinazoline inhibitors, we decided to better characterize the 
enzymatic activity of EML741 by studying the kinetic mechanism of G9a inhibition, 
again by means of the AlphaLISA® technology. 
Therefore, the inhibitory effect of EML741 was explored by performing two 
sets of experiments, at three different concentrations (0, 7.25 and 14.5 nM). In one 
case, enzyme activity was measured by keeping constant the histone H3 peptide 
substrate concentration while varying the cofactor (SAM) concentration. In the 
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other set, the SAM concentration was constant while the H3 peptide concentration 
was varied. 
The double-reciprocal plots obtained are showed in Figure 4.4. In particular, as 
it lowered the Vmax value, EML741 showed non-competitive inhibition versus the 
cofactor (Ki of 3.6 ± 0.6 nM, Figure 4.4 A). Conversely, EML741 exhibited 
competitive inhibition for the histone H3 peptide substrate as it increased the Km 
while leaving unaffected the Vmax, resulting in a Ki value of 13.8 ± 1.7 nM (Figure 
4.4 B). These results are in line with those reported by Vedadi et al. for UNC0638 
(Ki = 3.00 ± 0.05 nM).
120 
 
Figure 4.4 A, Plot of 1/v vs 1/[SAM] at a fixed H3 concentration (100 nM) 
and three different concentrations of EML741 shows noncompetitive inhibition. 
EML741 Ki = 3.6 ± 0.6 nM, α Ki = 1.1 ± 0.2 nM, SAM apparent Km = 164 ± 21 
µM. B, Plot of 1/v vs 1/[H3] at a fixed SAM concentration (15 μM) and three 
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different concentrations of EML741 shows competitive inhibition. EML741 Ki = 
13.8 ± 1.7 nM, H3 apparent Km = 1.6 ± 0.3 μM. 
 
4.3 Chemical stability assay 
Small-molecules can be unstable in aqueous solutions and this can 
significantly limit their application as molecular probes.  
In compound EML741 we envisioned the imino group as a putative point of 
chemical instability, as it could be hydrolyzed in aqueous medium. Therefore, the 
compound was incubated with PBS solution, at room temperature. The presence of 
degradation products in the sample was assessed by HPLC analysis after 12, 24, 48 
and 72 hours (Figure 4.5).  
 
 
Figure 4.5 HPLC chromatograms obtained for compound EML741 injected 
immediately after the dissolution in PBS, after 12, 24, 48 and 72 h. Spectra were 
recorded at 220 nm. 
 
Experimental results indicated that EML741 is stable under the conditions 
routinely used in biochemical and biological assays, up to 72 hours.  
 
4.4 Cell Permeability: Parallel artificial membrane permeability assay  
Among the factors influencing the pharmacokinetic properties, a good 
permeability profile is widely recognized as an important characteristic of both 
chemical probes and drug candidates, as it strongly influences, for example, 
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gastrointestinal absorption, permeation of the blood–brain barrier (BBB) and, 
ultimately, whether a compound is able to reach the intracellular targets.165 
Indeed, as discussed in Chapter 1, despite the good number of compounds 
with good potency and high selectivity for inhibiting G9a, a poor membrane 
permeability has frequently limited their use in cell-based assays and, therefore, the 
study of G9a involvement in both physiological and pathological pathways. 
Parallel artificial membrane permeability assay (PAMPA) is a well-validated 
technique to estimate the ability of a compound to permeate model membranes.166-
167 In fact, due to its robustness, versatility and easy set-up, nowadays several 
PAMPA models have been developed, displaying a high degree of correlation with 
permeation across a variety of barriers (such as skin, gastrointestinal tract and 
blood–brain barrier).167-170 
Therefore, we exploited this technique to evaluate the cell permeability of 
EML741 using the highly permeable drug propranolol, the poorly permeable drug 
furosemide and the UNC0638 as references. Moreover, being interested in 
developing novel chemical probes for REST-expressing MBs models, we 
performed a PAMPA-BBB assay to estimate its ability to cross the blood–brain 
barrier. In this case, also the highly permeable drug chlorpromazine was used as 
reference (Table 4.3). 





EML741 4.80 × 10-7 2.30 × 10-7 
UNC0638 0.49 × 10-7 n.d.b 
Propranolol 54.0 × 10-7 52.0 × 10-7 
Furosemide u.d.l.a u.d.l.a 
Chlorpromazine n.d.b 6.60 × 10-7 
a under detection limit; b not determined 
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EML741 showed an interesting apparent permeability value (Papp) of 4.80 × 
10-7 cm/s, higher than the UNC0638 (Papp = 0.49 × 10
-7 cm/s). Moreover, it showed 
a good Papp value (2.30 × 10
-7 cm/s) also using porcine brain lipid extract as 
membrane, mimicking the blood−brain barrier.  
 
4.5 Cell-based assays: preliminary results 
On the basis of these encouraging results, cell-based assays were planned and 
are now ongoing. In particular, we want to study the ability of EML741 to reduce 
H3K9me2 levels in three tumor cell lines (MCF-7, MDA-MB-231, U343), detected 
by immunoblotting. Cell-cycle alteration will be also evaluated.  
To date, preliminary data on the human breast cancer cell line MCF7 have 
already been collected. For comparative purposes, UNC0638 was assayed in the 
same conditions.  
MCF-7 were treated with EM741 with doses ranging from 0.05 to 50 µM. 
After 24, 48 and 72 hours of incubation, the percentage of viable cells in the treated 
samples, with respect to cells treated with an equal amount of DMSO (0.5% final 
concentration), was evaluated by means of methylthiazoletetrazolium (MTT) 
viability assay.  
Interestingly, it was observed that EM741 did not induce a strong reduction of 
the cell viability even at the higher dose and longer incubation time, while at the dose 
of 50 µM UNC0638 resulted cytotoxic even after 24 hours (Figure 4.6). 




Figure 4.6 Cytotoxic effect of EML741 and UNC0638 on MCF7 cell line. 
Cells were seeded and allowed to adhere overnight, after which were treated with 
the indicated doses of both compounds and an equal amount of DMSO was used as 
control. Data were normalized with respect to control and the results are shown as 
the mean ± SD of four independent experiments.  
 
Subsequently, we evaluated the effects on the cellular level of H3K9me2 after 
48 and 72 hours incubation with 0.5 and 5.0 µM of EML741. After the treatment, 
the histone extracts were immunoblotted with an antibody specific for the 
abovementioned modification, using total histone H4 as loading control. An equal 
amount of DMSO was used to treat the control sample. As shown in Figure 4.7, 
EML741 induced a significant dose and time dependent decrease in the H3K9me2 
levels in bulk histones, in a comparable manner to 0.5 µM UNC0638, used as a 
reference.  
 




Figure 4.7 Western blot analysis of H3K9me2 level after treatment of MCF7 
cells with EML741 and UNC0638. Cells were seeded and allowed to adhere 
overnight, after which were treated with the indicated doses of both compounds or 
DMSO. Signals were detected with the ImageQuant LAS 4000 digital imaging 
system and quantified by ImageQuantTL software (version 8.1); total histone H4 
levels were used for normalization. The results are reported as the mean ± SD of 
three independent experiments. 
 
 
Further studies on other tumor cell lines will deeply elucidate the role of 
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Pursuing my efforts toward the identification of novel molecular entities that 
could serve as useful probes to elucidate both the physiological and the pathological 
role of G9a, I decided to spend 6 months of my PhD period in the group of Dr. Stefan 
Kubicek at CeMM (the Research Center of Molecular Medicine of the Austrian 
Academy of Science). The Kubicek laboratory hosts the PLACEBO (Platform 
Austria for Chemical Biology), which facilitates the access to chemical biology 
resources, including a vast compound library (comprising more than 90.000 small 
molecules) and HTS/HCS equipment, needed for the identification and 
characterization of small molecules to be used for the interrogation of biological 
processes as well as in drug discovery. Recently in the Kubicek group, S. Sdelci 
and co-workers published a Nature Chemical Biology article describing the 
generation of a fluorescent reporter cell line monitoring the inhibition of BRD4,144 
an epigenetic reader involved in transcription initiation and super enhancer 
formation. Inspired by that, I wanted to develop a cellular reporter system able to 
respond to epigenetic changes induced by G9a inhibition by enhancing the 
expression of a fluorescent protein. 
As previously mentioned (Chapter 2), reporter gene technology is a valuable 
tool to monitor the cellular events associated with signal transduction and gene 
expression. The main advantages of this method are the high sensitivity and 
reliability, and suitability for large-scale measurements. The possibility of using a 
reporter gene t echnology in HTS makes cell-based assays an extremely attractive 
alternative to in vitro biochemical assays, as they better mimic physiological 
conditions.142 
 
5.1 Generation of a reporter cell line for the inhibition of G9a 
To generate a reporter cell line that specifically activate the expression of a 
fluorescent reporter phenocopying G9a inhibition, we used lentivirus particles 
encoding for a blue fluorescent protein (BFP). Lentiviral vectors are based on 
human immunodeficiency virus (HIV) and, to date, they are a validated research 
tool for gene knockdown, gene over expression efficient in vivo gene delivery (gene 
therapy). In fact, unlike other retroviruses, lentiviral vectors do not necessarily 
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require cell division for proviral integration and productive infection. Lentiviruses 
also transduce cells with high efficiency and stability of transgene expression.171-
172  
The BFP-lentiviral particles mentioned above were generated in 293T human 
kidney cells (HEK293T) by transient transfection of the vector of interest (pLV-
BFP) together with the packaging (psPAX2) and the envelop plasmids (VSV-G). 
The virus-containing supernatant was collected after 30, 48 and 72 hours of 
transfection.  
Aiming at performing chemical and genetic screenings with the developed 
reporter cell line, we chose as model the chronic myelogenous leukemia human cell 
line KBM7, which has a near-haploid karyotype and therefore allows unambiguous 
monoallelic genetic configurations.173-174 
Before performing the BFP-lentiviral infection, we treated KBM7 cells with 
UNC0638, in order to induce chromatin remodeling in a G9a-inhibition specific 
manner. In this way, the integration of the fluorescent reporter can happen in a 
usually condensed locus of the genome which becomes open following G9a 
inhibition. To determine the activity-toxicity window of UNC0638 on these cells, 
wild type (wt) KBM7 cells were treated in five-point dose response for 24 and 48 
hours. Western blot analysis in combination with CellTiter-Glo® Luminescent Cell 
Viability Assay (Promega) have shown that after 48 hours of incubation, UNC0638 
2 µM was able to significantly reduce H3K9me2 levels, without drastically 
impairing cell viability (Figure 5.1).  
 
 




Figure 5.1. A, Western blot analysis of H3K9me2 methylation (H3 has been 
used as loading control) and B, Cell-Titer Glo® assay after treatment of wt KBM7 
cells for 48 hours with the indicated amounts of UNC0638. Data were normalized 
with respect to control and the results are shown as the mean ± SD of three 
independent experiments. 
 
Once chosen 2 µM as better UNC0638 performing concentration, we treated 
KBM7 in order to first induce chromatin remodeling. After 48 hours, treated cells 
were infected with BFP lentiviral particles, and 48 hours later sorted for their ability 
of expressing the BFP protein. The sorted population was plated in fresh media in 
absence of UNC0638, let recover in culture for additional 5 days, whereupon BFP-
negative cells were sorted. With this double sorting strategy, we were able to select 
a population of cells that express BFP when G9a is inhibited and repress the 
fluorescent reporter after withdrawal of the compound (SWITCH-ON) (Figure 5.2).  
 
 
Figure 5.2 Pipeline of the experimental approach. 
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Gates for BFP-positive/negative populations were done using wild type 
KBM7 as negative control. Exemplificative sorting analyses are reported in Figure 
5.3.  
 
Figure 5.3 Sorting analysis of wt KBM7 population (not infected; left panel), 
the infected and sorted population colored by increasing BFP intensity (from gray 
to blue). Cells were selected based on high BFP expression after infection (blue 
rectangle; middle panel) and BFP negativity after drug withdrawal (black rectangle, 
right panel).  
 
Finally, to obtain a pure population, single cell sorting was performed, and 
outgrowing clones were further analyzed to select the best performing based on 
their ability of robustly express BFP in live-cell imaging (Figure 5.4). Briefly, all 
the reporter cell lines were first treated with a single concentration of UNC0638 (2 
μM) to select SWITCH-ON positive clones which were further characterized in dose 
response assay (from 2.0 to 20 μM). Due to their strong BFP expression upon 
UNC0638 treatment, clones 1704001-A7 and 1704014-H3 were chosen for further 
studies.  
 
Figure 5.4 Representative pictures of live cell imaging of a SWITCH-ON cell 
line. 
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5.2 Validation and preliminary results 
To rule out the specificity of 1704001-A7 and 1704014-H3 detecting G9a 
inhibition, but also to identify new small molecules able to phenotypically mimic 
the effect of UNC0638, we performed a small molecule screening using a small 
library of 2000 compounds. Among the 90K compounds available at PLACEBO, 
these 2000 have an annotated target. In particular, 274 epigenetic inhibitors consent 
to thoroughly evaluate the ability of the cell line to detect G9a inhibition among 
other epigenetic perturbations. Moreover, other compounds resulting in an effective 
activation of BFP expression could represent a first pool of hits to validate or, 
having an annotated target, could give us a hint regarding G9a biology.  
During the primary screening, 1704001-A7 and 1704014-H3 clones were 
treated in single dose of each compound, and 24 hours later live-cell imaging 
pictures were taken to assess their ability to induce BFP expression. UNC0638 10 
and 20 µM were used as positive control, while DMSO was used as negative 
control. In order to select hit compounds, we used a software able to count BFP-
positive cells; a given small molecule was selected as hit when the number of BFP 
positive cells exceeded the DMSO average plus 4× standard deviation (SD). Hits 
distribution from the preliminary screening on one clone is showed as dot plot in 
Figure 5.5.  
  




Figure 5.5 Dot plot representing the hits distribution from the primary 
screening on 1704011-A7 cell line.  
 
The small molecules selected as hits in the primary screening were used to 
treat wt KBM7 to exclude autofluorescent or toxic compounds. To this point, 18 
small molecules were selected used to treat both reporter cell lines in parallel with 
wt KBM7 cells in eight-point dose in order to carefully select the best performing 
compounds (Figure 5.6 A). Finally, only 5 compounds confirmed as good hits 
(Figure 5.6 B) and for those the mechanism of action has to be clarified. 




Figure 5.6 A, Pipeline for the selection of hits. DR: dose-response; B, 
selected hits from the performed screens.  
 
To confirm the results using a different technology, we performed a real time 
PCR (RT-PCR) to detect the increase of BFP expression following the treatment 
with the selected compounds, at the transcriptional level. All the G9a inhibitors 
available at PLACEBO (BIX01294, UNC0224, UNC0642 and A366) were used as 
positive controls (Figure 5.7).  
 



































































































































Figure 5.7 BFP expression performed by RT-PCR in 1704001-A7 cells 
treated with indicated compounds and doses for 24 hours. An equal volume of 
DMSO was used as negative control. Two replicates were performed for each 
experimental condition (mean  SD). 
 
Among the G9a inhibitors, BIX01294 and UNC0642 increased the BFP 
expression in a manner comparable to UNC0638. On the other hand, neither 
UNC0224 nor A366 induced such increase. It is worth noting that, to the best of 
our knowledge, UNC0224 is reported as good G9a inhibitor in vitro, while its 
activity in cell-based assays was not investigated. Instead, as regards A366, few 
considerations have already been touched on in Chapter 1. Regarding the 2K 
screening hits, the RT-PCR data confirmed the increase of the BFP expression, in 
a comparable manner with respect to the lower dose of UNC0638. A deeper 
characterization of the molecular mechanism underlying the activation of the reporter 
is needed to elucidate their link to G9a biology.  
Further validation experiments, such as G9a/GLP knock down and a genome-
scale screening using a CRISPR/Cas9 Knockout Library (Brunello) are currently 
ongoing. Once the specificity is definitely confirmed, a 90Kcompound library 
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Because of its central role in many biological processes, and therefore, its 
involvement in several pathological conditions, the lysine methyltransferase G9a is 
considered a valuable drug target for the development of novel therapeutic 
strategies and, in particular, for cancer therapy (e.g. REST-expressing MBs). 
Therefore, in the past decades several research groups focused their efforts towards 
the development of potent and selective G9a inhibitors. However, since the 
chemical diversity of current available G9a inhibitors is very limited, the 
development of novel chemotypes is extremely desirable.  
In this regard, my PhD project was aimed to the identification of novel 
chemotypes as G9a modulators by means of two different approaches. The first, 
basically relying on a medicinal chemistry perspective, considered the modification 
of the central core structure of the most used G9a chemical probe, UNC0638. The 
replacement of the quinazoline moiety of the UNC0638 with a “privileged” 
benzodiazepine nucleus led to the compound EML741. The central core of our 
ring-expanded derivative consist of a 3H-benzo[e][1,4]diazepine nucleus, whose 
synthesis was optimized by means of a continuous-flow protocol. EML741 and a 
small set of analogues were synthesized and their ability of inhibiting G9a was 
assessed in vitro. EML741 was able to inhibit G9a to the same extent as the parent 
compound UNC0638 (IC50 = 0.023 µM and IC50 = 0.025 µM, respectively), while 
it did not significantly affect the activity of a small panel of selected epigenetic 
enzymes, up to 25 µM. Furthermore, kinetic studies confirmed EML741 as a 
substrate competitive and cofactor non-competitive inhibitor. These encouraging 
results, together with a promising membrane permeability profile (PAMPA and 
PAMPA-BBB), prompted us to better characterize the activity profile of EML741 
in tumor cell lines. These studies, currently ongoing, are aimed to assess its potential 
as new valuable lead for the development of a novel class of G9a modulators, to 
further validate G9a as drug target in cancer therapy, and in particular in REST-
expressing MBs.  
On the other hand, we considered to expand the chemical space of G9a 
modulators through a biological approach, generating a new cell-based screening 
platform. To this end, the human haploid cell line KBM7 was incubated with the 
G9a inhibitor UNC0638 to induce the reactivation of G9a-silenced regions, then 
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infected with a lentivirus encoding for a blue fluorescent protein. Applying multiple 
fluorescence-activated cell sorting (FACS) steps, we selected two population able 
to increase the expression of the reporter protein upon treatment with the G9a 
inhibitor. The specificity of these reporter cell lines to detect G9a inhibition was 
evaluated by excluding its expression in response to different epigenetic 
perturbations. A small library of about 2000 compounds was screened and 5 
compounds were identified as hits. The molecular mechanism behind this activation 
has to be elucidated. Before moving on to large-scale screening, additional 
validation experiments are now ongoing. This approach laid the groundwork for a 
systematic search of novel chemical entities that interfere with G9a activity, as well 
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General directions. All chemicals were purchased from Sigma Aldrich 
(Milan, Italy) or from Fluorochem Ltd (Hadfield, United Kingdom) and were of the 
highest purity. All solvents were reagent grade and, when necessary, were purified 
and dried by standard methods. All reactions requiring anhydrous conditions were 
conducted under a positive atmosphere of nitrogen in oven-dried glassware. 
Standard syringe techniques were used for anhydrous addition of liquids. Reactions 
were routinely monitored by TLC performed on aluminum-backed silica gel plates 
(Merck DC, Alufolien Kieselgel 60 F254) with spots visualized by UV light (λ = 
254, 365 nm) or using a KMnO4 alkaline solution. Solvents were removed using a 
rotary evaporator operating at a reduced pressure of ∼10 Torr. Organic solutions 
were dried over anhydrous Na2SO4. Chromatographic purification was done on an 
automated flash chromatography system (IsoleraOne™, Biotage) using cartridges 
packed with KP-SIL, 60 Å (40−63 μm particle size). High performance liquid 
chromatography (HPLC) was performed on a Shimadzu SPD 20A UV/vis detector 
(λ = 220 nm) using C-18 column Phenomenex Synergi Fusion RP 80A (75mm × 
4.60 mm; 4 μm) at 25 °C using a mobile phase A (water + 0.1% TFA) and B (ACN 
+ 0.1% TFA) at a flow rate of 1 mL/min. Preparative HPLC was performed using 
an Shimadzu Prominence LC-20AP with the UV detector set to 220 nm and 254 
nm. Samples were injected onto a Phenomenex Synergi Fusion – RP 80A (150× 21 
mm; 4 µm) C18 column at room temperature. Mobile phases of A (water + 0.1% 
TFA) and B (ACN + 0.1% TFA) were used with a flow rate of 20 mL/min. A 
general gradient of 0–3 minutes at 15% B, 3–30 minutes increasing from 15 to 40% 
B, and 30–33 minutes increasing from 40 to 90% B was used, followed by a 90% 
B flush for another 2 minutes. Small variations in this purification method were 
made as needed to achieve ideal separation for each compound.1H NMR spectra 
were recorded at 300 MHz on a Bruker Avance 300 spectrometer or at 400 MHz 
on a Bruker Avance 400 III HD. 13C NMR spectra were recorded at 100 MHz on a 
Bruker Avance 400 III HD. Chemical shifts are reported in δ (ppm) relative to the 
internal reference tetramethylsilane (TMS). Mass spectra were recorded on a 
Biotage Dalton 2000 (Uppsala, Sweden) mass spectrometer in atmospheric pressure 
chemical ionization, in positive and negative modes. High-resolution mass 
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spectrometry (HRMS) analysis was performed using Bruker SolariX XR 7T FT-
ICR mass spectrometer in electrospray (ESI) positive ionization mode. Purity of tested 
compounds was ≥95%, established by HPLC analysis.  
 
7.1.1 Preparation of 2-nitrobenzamides 2a-c 
7.1.1.1 Procedures for the preparation of 4-(benzyloxy)-5-methoxy-2-nitrobenzoic 
acid (3) 
Synthesis of ethyl 4-hydroxy-3-methoxybenzoate (6) 
 
A mixture of vanillic acid (10 g, 59.5 mmol) and sulfuric acid (1.6 mL, 2.94 
mmol) in anhydrous ethanol (50 mL) was heated under reflux for 8 h. The reaction 
mixture was concentrated under vacuum, taken up with NaHCO3 saturated solution 
(75 mL) and extracted with EtOAc (3 × 100 mL). The combined organic layers 
were washed with brine, dried, filtered, and concentrated in vacuo affording the 
desired product as brown oil (11.5 g, 99%). 1H NMR (300 MHz, DMSO-d6) δ 9.95 
(br s, 1H exchangeable with D2O), 7.72 – 7.24 (m, 2H), 6.86 (d, J = 8.2 Hz, 1H), 
4.25 (q, J = 6.9 Hz, 2H), 3.81 (s, 3H), 1.29 (t, J = 7.0 Hz, 3H); MS: m/z 195 [M – 
H-]. 
 
Synthesis of ethyl 4-(benzyloxy)-3-methoxybenzoate (7) 
 
To a solution of ethyl 4-hydroxy-3-methoxybenzoate 6 (11.6 g, 59.1 mmol) 
in DMF (50 mL), potassium carbonate (12.3 g, 88.7 mmol) and benzyl bromide 
(11.1 g, 65.0 mmol) were added. The reaction mixture was stirred at room 
temperature overnight. Water was added to precipitate the product which was 
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filtered under vacuum, through a por.3 Gooch, and washed thoroughly with water. 
White solid (15.4 g, 90%); 1H NMR (300 MHz, DMSO-d6) δ 7.57 (dd, J = 8.5, 2.0 
Hz, 1H), 7.51 – 7.30 (m, 6H), 7.17 (d, J = 8.5 Hz, 1H), 5.17 (s, 2H), 4.28 (q, J = 7.0 
Hz, 2H), 3.82 (s, 3H), 1.30 (t, J = 7.1 Hz, 3H); MS: m/z 287 [M + H+]. 
 
Synthesis of ethyl 4-(benzyloxy)-5-methoxy-2-nitrobenzoate (8) 
 
To an ice-cooled solution of ethyl 4-(benzyloxy)-3-methoxybenzoate 7 (15.3 
g, 53.3 mmol) in acetic anhydride (175 mL) was added fuming nitric acid (13.7 mL, 
309 mmol) dropwise. The reaction mixture was allowed to slowly warm to room 
temperature and stirred overnight. The mixture was poured into ice-water and the 
resulting precipitate was filtered through a por.3 Gooch, washed with water, and 
dried to provide ethyl 4-(benzyloxy)-5-methoxy-2-nitrobenzoate (16.3 g, 92%). 
Yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 7.76 (s, 1H), 7.49 – 7.34 (m, 5H), 
7.32 (s, 1H), 5.26 (s, 2H), 4.29 (q, J = 7.1 Hz, 2H), 3.92 (s, 3H), 1.27 (t, J = 7.1 Hz, 
3H); MS: m/z 332 [M + H+]. 
 
Synthesis of 4-(benzyloxy)-5-methoxy-2-nitrobenzoic acid (3) 
 
Ethyl 4-(benzyloxy)-5-methoxy-2-nitrobenzoate 8 (13.4 g, 40.5 mmol) was 
dissolved in THF (191 mL) and 2 N NaOH solution (61 mL) was added. The 
reaction mixture was stirred at room temperature for 24 h, then concentrated in 
vacuo. The residue was diluted with 1 N NaOH aqueous solution (50 mL) and 
washed with ether (3 × 50 mL). The aqueous phase was acidified with 6 N HCl 
aqueous solution till pH 1 and extracted with EtOAc (3 × 75 mL). The combined 
organic layers were washed with brine, dried, filtered, and concentrated under 
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reduced pressure to afford the desired product 3 as yellow solid (12.1 g, 98%); 1H 
NMR (300 MHz, DMSO-d6) δ 13.61 (br s, 1H exchangeable with D2O), 7.69 (s, 
1H), 7.53 – 7.33 (m, 5H), 7.30 (s, 1H), 5.24 (s, 2H), 3.91 (s, 3H); MS: m/z 302 [M 
– H-]. 
 
7.1.1.2 Procedures for the preparation of α-aminoketones (4a-c) 
Synthesis of 2-azido-1-phenylethan-1-one (10) 
 
To an ice-cooled solution of 2-bromoacetophenone (5.0 g, 25.1 mmol) in 
DMF (60 mL) was added sodium azide (4.9 g, 75.4 mmol). The reaction mixture 
was stirred at 0 °C for 30 min, then diluted with water (40 mL) and EtOAc (40 mL). 
The phases were separated and the aqueous layer was extracted twice with EtOAc 
(2 × 40 mL). The combined organic layers were then washed with NaHCO3 
saturated solution (3 × 30 mL) and brine (50 mL), dried over Na2SO4, filtered, and 
concentrated in vacuo, affording the desired product (10) as yellow oil (4.0 g, 98%). 
Known compound. NMR data are consistent with those reported. 1H NMR (400 
MHz, Chloroform-d)  7.92 – 7.89 (m, 2H), 7.63 – 7.59 (m, 1H), 7.52 – 7.50 (m, 
2H), 4.56 (s, 2H);175 MS: m/z 162 [M + H+]. 
 
Synthesis of 2-amino-1-phenylethan-1-one hydrochloride (4a) 
 
The 2-azido-1-phenylethan-1-one 10 (4.0 g, 24.8 mmol) was dissolved in 
MeOH (50 mL) and the solution was cooled at 0 °C. Then, 12 N HCl aqueous 
solution (3.0 mL) and triphenylphosphine (7.2 g, 27.3 mmol) were added. The 
reaction mixture was allowed to warm to room temperature and stirred overnight. 
The reaction mixture was diluted with 6 N HCl aqueous solution (15 mL) and 
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evaporated under reduced pressure to provide the 2-amino-1-phenylethan-1-one 
hydrochloride, which was directly in the next step, without further purification, 
considering a quantitative conversion of limiting reagent. 
  
Synthesis of tert-butyl (2-(methoxy(methyl)amino)-2-oxoethyl)carbamate (12) 
 
A solution of N-(Boc)glycine (5.0 g, 28.5 mmol) in anhydrous THF (40 mL) 
was cooled to 0 °C and 1,1-carbonyldiimidazole (CDI; 5.6 g, 34.3 mmol) was added 
portion-wise. The mixture was stirred at 0 °C for 15 minutes, then at room 
temperature for 1 h. N,O-dimethylhydroxylamine hydrochloride (3.3 g, 37.1 mmol) 
and triethylamine (5.2 mL, 37.1 mmol) were added in this order and the resulting 
suspension was stirred at room temperature overnight. After this time, the mixture 
was filtered and the filtrate evaporated to dryness. The residue was taken up with 
EtOAc (150 mL) and washed with 1 N HCl aqueous solution (3 × 50 mL), NaHCO3 
saturated solution (3 × 50 mL), brine (50 mL), dried over Na2SO4, filtered, and 
concentrated in vacuo, affording the desired product (12) as white solid (5.0 g, 
80%). Known compound. NMR data are consistent with those reported. 1H NMR 
(400 MHz, Chloroform-d) δ 5.28 (s, 1H), 4.10 (d, J = 4.8 Hz, 2H), 3.74 (s, 3H), 
3.23 (s, 3H), 1.48 (s, 9H);176 MS: m/z 219 [M + H+]. 
 
Synthesis of tert-butyl (2-cyclohexyl-2-oxoethyl)carbamate (13b) 
 
Tert-butyl (2-(methoxy(methyl)amino)-2-oxoethyl)carbamate 12 (4.40 g, 
20.2 mmol) was dissolved in anhydrous THF (50 mL) and cooled to -15 °C. Then, 
cyclohexylmagnesium chloride (2.0 M solution in Et2O, 21.1 mL) was added 
slowly, via syringe, and the resulting mixture was stirred at -15 °C for 1 h, and then 
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gently warmed to room temperature and stirred at the same temperature for 1 h. The 
reaction was quenched with NH4Cl satured solution and extracted with diethyl ether 
(3 × 100 mL). The organic phase was washed with brine, dried, filtered and 
concentrated under reduced pressure. The residue was purified by silica gel 
chromatography (n-Hex/EtOAc) to give the title compound as colorless oil (2.48 g, 
50%); 1H NMR (300 MHz, DMSO-d6) δ 6.94 (t, J = 5.2 Hz, 1H exchangeable with 
D2O), 3.80 (d, J = 5.8 Hz, 2H), 2.46 – 2.31 (m, 1H), 1.81 – 1.53 (m, 5H), 1.37 (s, 
9H), 1.28 – 1.08 (m, 5H); MS: m/z 242 [M + H+]. 
 
Synthesis of tert-butyl (3-methyl-2-oxobutyl)carbamate (13c) 
 
Synthesized in 45% yield using isopropylmagnesium chloride solution 2.0 M 
in THF, following the procedure described for 13b. Colorless oil; 1H NMR (300 
MHz, DMSO-d6) δ 6.96 (t, J = 5.2 Hz, 1H exchangeable with D2O), 3.82 (d, J = 
5.9 Hz, 2H), 2.80 – 2.60 (m, 1H), 1.37 (s, 9H), 1.00 (d, J = 6.9 Hz, 6H); MS: m/z 
202 [M + H+]. 
 
Synthesis of 2-amino-1-cyclohexylethan-1-one (4b) 
 
Tert-butyl (2-cyclohexyl-2-oxoethyl)carbamate 13b (3.20 g, 13.3 mmol) was 
dissolved in 1:1 CH2Cl2/TFA (6 mL) and the solution was stirred at room 
temperature for 2 h. The reaction mixture was then diluted with toluene and 
evaporated under reduced pressure. The crude product was directly used in the next 
step without further purification, considering quantitative conversion of limiting 
reagent.  
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Synthesis of 1-amino-3-methylbutan-2-one (4c) 
 
Synthesized starting from compound 13c following the procedure described 
for 4b. The crude product was directly used in the next step without further 
purification, considering quantitative conversion of limiting reagent. 
 
7.1.1.3 Procedures for the synthesis of 2-nitrobenzamides (2a-c) 
Synthesis of 4-(benzyloxy)-5-methoxy-2-nitro-N-(2-oxo-2-phenylethyl) 
benzamide (2a) 
 
To an ice cooled suspension of 4-(benzyloxy)-5-methoxy-2-nitrobenzoic acid 
3 (1.30 g, 4.29 mmol), HOBt·H2O (1.58 g, 10.3 mmol), HBTU (3.91 g, 10.3 mmol) 
in a mixture THF/DMF (100 mL; 4:1 ratio), N,N-diisopropylethylamine (DIPEA) 
(3.59 mL, 20.6 mmol) was added. The reaction mixture was stirred at room 
temperature for 15 min and then 2-amino-1-phenylethan-1-one hydrochloride (4a, 
0.88 g, 5.15 mmol) was added. The mixture was stirred at room temperature for 12 
h and then it was concentrated in vacuo and EtOAc (60 mL) was added. The organic 
layer was washed with NaHCO3 saturated solution (3 × 20 mL), dried, and 
concentrated. Recrystallization from ethanol provided the title compound (1.52 g, 
84 %) in high purity grade. 1H NMR (300 MHz, DMSO-d6) δ 8.95 (t, J = 5.5 Hz, 
1H exchangeable with D2O), 8.06 – 8.04 (m, 2H), 7.73 – 7.67 (m, 2H), 7.60 – 7.55 
(m, 2H), 7.49 – 7.31 (m, 5H), 7.15 (s, 1H), 5.26 (s, 2H), 4.79 (d, J = 5.5 Hz, 2H), 
3.94 (s, 3H); MS: m/z 421 [M + H+]. 
 






Synthesized in 70% yield starting from compounds 3 and 4b following the 
procedure described for 2a. White solid. 1H NMR (300 MHz, DMSO-d6) δ 8.80 (t, 
J = 5.6 Hz, 1H exchangeable with D2O), 7.72 (s, 1H), 7.49 – 7.35 (m, 5H), 7.13 (s, 
1H), 5.25 (s, 2H), 4.15 (d, J = 5.6 Hz, 2H), 3.93 (s, 3H), 2.62 – 2.56 (m, 1H), 1.84 





Synthesized in 85% yield starting from compounds 3 and 4c following the 
procedure described for 2a. White solid. 1H NMR (300 MHz, DMSO-d6) δ 8.80 (t, 
J = 5.5 Hz, 1H exchangeable with D2O), 7.72 (s, 1H), 7.48 – 7.34 (m, 5H), 7.12 (s, 
1H), 5.25 (s, 2H), 4.18 (d, J = 5.5 Hz, 2H), 3.92 (s, 3H), 2.89 – 2.73 (m, 1H), 1.05 
(d, J = 7.0 Hz, 6H); MS: m/z 387 [M + H+]. 
 
7.1.2 General procedures for the reduction of 2-nitrobenzamides 2a-c 
Methods A, E, F and G. The proper catalyst was added to a solution of the 
appropriate 2-nitrobenzamide (0.60 mmol) in a mixture EtOAc/EtOH (20 mL; 2:1 
ratio) and the reaction was stirred under H2 (1 atm, balloon) at room temperature. 
The reaction mixture was filtered, concentrated and the residue was purified by 
silica gel chromatography (CH2Cl2/MeOH). 
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Method B. A 10 mL CEM microwave process vial with a stir bar was charged 
with the appropriate 2-nitrobenzamide 2 (0.10 mmol), 10 wt. % Pd/C (0.05 eq), and 
methanol (1 mL). 1,4-cyclohexadiene (57 µL, 0.60 mmol) was added. The vessel 
was capped and heated under microwave conditions at 120 °C for 10 min. The 
reaction was filtered through Celite, concentrated and the residue was purified by 
silica gel chromatography (CH2Cl2/MeOH). 
Method C. A boiling solution of the appropriate 2-nitrobenzamide 2 (0.60 
mmol) in ethanol (3 mL) was added to a suspension of iron (II) sulfate heptahydrate 
(1.67 g, 6.00 mmol) in water (3 mL) and 32% ammonium hydroxide solution (0.30 
mL). The reaction mixture was heated under reflux until the disappearance of the 
starting material (TLC analysis) while 32% ammonium hydroxide was dropped (3 
mL). The hot mixture was then filtered, concentrated and CHCl3 (50 mL) was 
added. The organic layer was washed with H2O (3 × 20 mL) and brine (1 × 50 mL), 
dried, and concentrated in vacuo. The residue was purified by silica gel 
chromatography (CH2Cl2/MeOH). 
Method D. Iron powder (0.67 g, 60.0 mg-atom) was added to a solution of 
the appropriate 2-nitrobenzamide 2 (0.60 mmol) in acetic acid (6 mL). The reaction 
mixture was heated at 70 °C until the disappearance of the starting material (TLC 
analysis). The mixture was diluted with water (20 mL) and CHCl3 (20 mL) and 
filtered through a small pad of Celite. After separation of the two phases, the 
aqueous layer was extracted with CHCl3 (2 × 20 mL). The organic phase was then 
washed with H2O (3 × 20 mL), NaHCO3 saturated solution (1 × 20 mL) and brine 
(1 × 20 mL), dried and concentrated in vacuo. The residue was purified by silica 
gel chromatography (CH2Cl2/MeOH). 
Method H (Continuous flow processing H-Cube ProTM hydrogenator) A 
10 mL stock solution of the appropriate 2-nitrobenzamide 2 with a 0.03 M 
concentration in THF was prepared in a glass vial. The reaction parameters (Full-
H2 mode, 80 °C, 50 bar and 0.3 mL/min flow rate) were selected on the H-Cube-
Pro™ hydrogenator. The instrument was fitted with a 30 mm 5% Ru/C CatCart and 
the processing was started, whereby initially only pure solvent was pumped through 
the system until the instrument had achieved the desired reaction parameters and 
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stable processing. At that point, the sample inlet line was switched to the vial 
containing the substrate. A total reaction volume of 15 mL was collected, and the 
cartridge subsequently washed with pure solvent for 5 min to remove any 
substrate/product still adsorbed on the catalyst. Evaporation of the solvent afforded 
the desired 3,4-dihydro-5H-benzo[e][1,4]diazepin-5-ones 1a–c (99% crude yield), 






White solid; 1H NMR (300 MHz, DMSO-d6): δ 8.41 (t, J = 5.8 Hz, 1H 
exchangeable with D2O), 8.06 – 8.03 (m, 2H), 7.55 – 7.33 (m, 9H), 7.02 (s, 1H), 
5.21 (s, 2H), 3.94 (d, J = 5.8 Hz, 2H), 3.85 (s, 3H). MS: m/z 373 [M + H+].  
 
8-(benzyloxy)-2-cyclohexyl-7-methoxy-3,4-dihydro-5H-benzo[e][1,4]diazepin-5-
one (1b)  
 
White solid; 1H NMR (300 MHz, DMSO-d6): δ 8.26 (t, J = 5.6 Hz, 1H 
exchangeable with D2O), 7.47 – 7.34 (m, 5H), 7.29 (s, 1H), 6.82 (s, 1H), 5.15 (s, 
2H), 3.81 (s, 3H), 3.40 (d, J = 5.6 Hz, 2H), 2.45 – 2.36 (m, 1H), 1.93 – 1.65 (m, 
5H), 1.42 – 1.17 (m, 5H); MS: m/z 379 [M + H+].  






White solid; 1H NMR (300 MHz, DMSO-d6): δ 8.31 (t, J = 5.6 Hz, 1H 
exchangeable with D2O), 7.48 – 7.35 (m, 5H), 7.31 (s, 1H), 6.85 (s, 1H), 5.17 (s, 
2H), 3.82 (s, 3H), 3.41 (d, J = 5.6 Hz, 2H), 2.83 – 2.70 (m, 1H), 1.18 (d, J = 6.8 Hz, 




Yellow oil. 1H NMR (300 MHz, DMSO-d6) δ 9.28 (br s, 1H exchangeable 
with D2O), 8.02 (t, J = 5.7 Hz, 1H exchangeable with D2O), 7.38 – 7.22 (m, 5H), 
7.05 (s, 1H), 6.14 – 6.13 (m, 3H, 2H exchangeable with D2O), 5.50 (d, J = 4.2 Hz, 
1H exchangeable with D2O), 4.77 – 4.71 (m, 1H), 3.67 (s, 3H), 3.25 – 3.17 (m, 2H); 
MS: m/z 303 [M + H+].   
 
8-hydroxy-7-methoxy-2-phenyl-1,2,3,4-tetrahydro-5H-benzo[e][1,4]diazepin-5-
one (15a)  
 
White solid; 1H NMR (300 MHz, DMSO-d6) δ 9.37 (br s, 1H exchangeable 
with D2O), 7.66 (t, J = 5.7 Hz, 1H exchangeable with D2O), 7.37 – 7.26 (m, 5H), 
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7.15 (s, 1H), 6.35 (s, 1H), 5.75 (s, 1H exchangeable with D2O), 4.66 (t, J = 5.7 Hz, 
1H), 3.69 (s, 3H), 3.37 – 3.33 (m, 2H); MS: m/z 285 [M + H+].  
2-cyclohexyl-8-hydroxy-7-methoxy-1,2,3,4-tetrahydro-5H-benzo[e][1,4]diazepin-
5-one (15b)  
 
White solid; 1H NMR (300 MHz, DMSO-d6) δ 9.23 (br s, 1H exchangeable 
with D2O), 7.68 (t, J = 5.8 Hz, 1H exchangeable with D2O), 7.16 (s, 1H), 6.21 (s, 
1H), 5.86 (d, J = 4.5 Hz, 1H exchangeable with D2O), 3.64 (s, 3H), 3.21 – 3.10 (m, 
2H), 3.03 – 3.00 (m, 1H), 1.77 – 1.62 (m, 5H), 1.45 – 1.36 (m, 1H), 1.23 – 0.87 (m, 





Yellow oil. 1H NMR (300 MHz, DMSO-d6) δ 8.40 (t, J = 5.8 Hz, 1H 
exchangeable with D2O), 8.06 – 8.03 (m, 2H) 7.55 – 7.33 (m, 11H, 2H 
exchangeable with D2O), 7.02 (s, 1H), 5.21 (s, 2H), 3.95 (d, J = 5.8 Hz, 2H), 3.85 
(s, 3H); MS: m/z 391 [M + H+].  
 






White solid; 1H NMR (300 MHz, DMSO-d6) δ 7.73 (t, J = 5.5 Hz, 1H, 
exchangeable with D2O), 7.48 – 7.26 (m, 10H), 7.20 (s, 1H), 6.61 (s, 1H), 6.22 (d, 
J = 3.6 Hz, 1H, exchangeable with D2O), 5.04 (s, 2H), 4.69 – 4.67 (m, 1H), 3.69 (s, 
3H); MS: m/z 375 [M + H+].  
 





Compound 1a (240 mg, 0.64 mmol) was dissolved in a mixture CH2Cl2/TFA 
(25 mL; 1:4 ratio). After stirring at 50 °C for 4 h, the reaction mixture was 
concentrated under reduced pressure. The residue was dissolved in EtOAc (20 mL), 
washed with NaHCO3 saturated solution (3 × 10 mL) and brine (20 mL). The 
organic phase was dried over sodium sulfate, filtered and evaporated to give the 
title compound (137 mg) in 75% yield as pale yellow solid. 1H NMR (400 MHz, 
DMSO-d6) δ 9.89 (br s, 1H exchangeable with D2O), 8.31 (t, J = 5.9 Hz, 1H 
exchangeable with D2O), 8.05 – 7.99 (m, 2H), 7.55 – 7.51 (m, 3H), 7.32 (s, 1H), 
6.76 (s, 1H), 3.92 (d, J = 5.9 Hz, 2H), 3.84 (s, 3H); MS: m/z 283 [M + H+].  






Synthesized in 68% yield starting from compound 1b following the procedure 
described for 18a. White solid; 1H NMR (400 MHz, DMSO-d6) δ 9.76 (br s, 1H 
exchangeable with D2O), 8.14 (t, J = 5.5 Hz, 1H exchangeable with D2O), 7.24 (s, 
1H), 6.58 (s, 1H), 3.79 (s, 3H), 3.37 (d, J = 5.6 Hz, 2H), 2.46 – 2.35 (m, 1H), 1.95 
– 1.61 (m, 5H), 1.43 – 1.10 (m, 5H); MS: m/z 289 [M + H+]. 
 
Synthesis of 8-(3-chloropropoxy)-7-methoxy-2-phenyl-3,4-dihydro-5H-
benzo[e][1,4]diazepin-5-one (19a)  
 
To a suspension of compound 18a (50 mg, 0.18 mmol) and potassium 
carbonate (108 mg, 0.78 mmol) in anhydrous DMF (1 mL), 1-chloro-3-iodopropane 
(159 mg, 0.78 mmol) was added. The reaction mixture was stirred, under nitrogen 
atmosphere, at room temperature overnight. The mixture was then diluted with 
EtOAc (60 mL) and washed with NaHCO3 saturated solution (3 × 20 mL) and brine 
(30 mL), dried over sodium sulfate, filtered and concentrated in vacuo. The crude 
was purified by silica gel chromatography (CH2Cl2/EtOAc), giving the desired 
product (49 mg) in 77% yield as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 
8.40 (t, J = 5.8 Hz, 1H exchangeable with D2O), 8.08 – 8.01 (m, 2H), 7.57 – 7.51 
(m, 3H), 7.35 (s, 1H), 6.94 (s, 1H), 4.20 (t, J = 6.1 Hz, 2H), 3.95 (d, J = 5.9 Hz, 
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2H), 3.85 (s, 3H), 3.80 (t, J = 6.5 Hz, 2H), 2.28 – 2.16 (m, 2H); MS: m/z (%) 359 





Synthesized in 71% yield starting from compound 18b following the 
procedure described for 19a. White solid; 1H NMR (400 MHz, DMSO-d6) δ 8.25 
(t, J = 5.7 Hz, 1H exchangeable with D2O), 7.27 (s, 1H), 6.73 (s,1H), 4.14 (t, J = 
6.1 Hz, 2H), 3.82 – 3.75 (m, 5H), 3.40 (d, J = 5.7 Hz, 2H), 2.47 – 2.41 (m, 1H), 
2.25 – 2.14 (m, 2H), 1.96 – 1.61 (m, 5H), 1.45 – 1.14 (m, 5H); MS: m/z (%) 365 





To an ice-cooled suspension of 19a (200 mg, 0.56 mmol) and sodium 
carbonate (59 mg, 0.56 mmol) in anhydrous CH2CH2 (4.2 mL), triethyloxonium 
tetrafluoroborate (212 mg, 1.12 mmol) was added. The reaction mixture was 
allowed to warm to room temperature and stirred for 15 minutes. The mixture was 
diluted with CH2CH2 (10 mL) and the organic phase was washed twice with brine 
(2 × 5 mL), dried over sodium sulfate, filtered and concentrated in vacuo. The 
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residue was purified by silica gel chromatography (n-Hex/EtOAc) to give the title 
compound (145 mg) in 67% yield as a yellow oil; 1H NMR (400 MHz, DMSO-d6) 
δ 8.12 – 8.02 (m, 2H), 7.56 – 7.48 (m, 3H), 7.24 (s, 1H), 7.00 (s, 1H), 4.26 – 4.10 
(m, 4H), 4.04 (br s, 2H), 3.85 (s, 3H), 3.81 (t, J = 6.5 Hz, 2H), 2.29 – 2.16 (m, 2H), 





Synthesized in 70% yield starting from compound 19b following the 
procedure described for 20a. Pale yellow oil; 1H NMR (400 MHz, DMSO- d6) δ 
7.16 (s, 1H), 6.80 (s, 1H), 4.21 – 4.06 (m, 4H), 3.85 – 3.75 (m, 5H), 3.51 (br s, 2H), 
2.47 – 2.40 (m, 1H), 2.28 – 2.11 (m, 2H), 2.01 – 1.58 (m, 5H), 1.45 – 1.14 (m, 8H); 






A 10 mL CEM pressure vessel equipped with a stirrer bar was charged with 
compound 20a (87 mg, 0.23 mmol), sodium iodide (34 mg, 0.22 mmol), potassium 
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carbonate (47 mg, 0.34 mmol), pyrrolidine (189 µL) and anhydrous THF (2.3 mL). 
The microwave vial was sealed and heated in a CEM Discover microwave 
synthesizer to 80 °C (measured by the vertically focused IR temperature sensor) for 
90 min. After cooling to room temperature, the reaction mixture was diluted with 
water (5 mL) and extracted with EtOAc (3 × 5 mL). The combined organic layers 
were washed with brine, dried, filtered, and concentrated in vacuo. The crude was 
purified by silica gel chromatography (CH2Cl2/MeOH/NH3) to afford the title 
compound (72 mg) in 76% yield as a brownish oil. 1H NMR (400 MHz, DMSO-d6) 
δ 8.13 – 8.05 (m, 2H), 7.58 – 7.48 (m, 3H), 7.24 (s, 1H), 6.98 (s, 1H), 4.21 – 4.10 
(m, 4H), 4.03 (br s, 1H), 3.86 (s, 3H), 2.80 – 2.57 (m, 6H), 2.05 – 1.92 (m, 2H), 





Synthesized in 74% yield starting from compound 20b following the 
procedure described for 21a. Brownish oil. 1H NMR (400 MHz, DMSO-d6) δ 7.13 
(s, 1H), 6.76 (s, 1H), 4.13 (q, J = 7.0 Hz, 2H), 4.07 (t, J = 6.5 Hz, 2H), 3.80 (s, 3H), 
3.47 (br s, 2H), 2.46 – 2.31 (m, 5H), 1.98 – 1.61 (m, 11H), 1.44 – 1.15 (m, 8H); 
MS: m/z 428 [M + H+]. 
 




1-yl)propoxy)-3H-benzo[e][1,4]diazepin-5-amine 22a (EML693) 
 
A 10 mL CEM pressure vessel equipped with a stirrer bar was charged with 
compound 21a (71 mg, 0.168 mmol), 4-amino-1-isopropyl piperidine (266 µL) and 
i-PrOH (600 µL). The microwave vial was sealed and heated in a CEM Discover 
microwave synthesizer to 200 °C (measured by the vertically focused IR 
temperature sensor) for 2 h. The crude material is diluted with a mixture ACN/H2O 
in 2:8 ratio and purified by reverse phase high-performance liquid chromatography 
(RP-HPLC) to afford the 3 × TFA salt of 22a as a yellow solid (45 mg, 31%). 1H 
NMR (400 MHz, D2O) δ 7.75 – 7.69 (m, 5H), 7.51 (s, 1H), 7.26 (s, 1H), 4.43 – 4.27 
(m, 3H), 4.09 (s, 3H), 3.86 – 3.74 (m, 2H), 3.67 – 3.54 (m, 3H), 3.49 (t, J = 7.5 Hz, 
2H), 3.29 – 3.09 (m, 4H), 2.48 – 2.32 (m, 4H), 2.31 – 2.13 (m, 4H), 2.12 – 1.98 (m, 
4H), 1.37 (d, J = 6.7 Hz, 6H); 13C NMR (100 MHz, D2O the signal of TFA was not 
included) δ 152.24, 149.67, 145.60, 140.71, 132.33, 131.31, 130.17, 129.60, 
129.08, 115.89, 101.53, 100.13, 66.77, 58.42, 56.25, 54.35, 52.71, 50.26, 47.78, 
30.59, 24.96, 22.64, 16.10; HRMS (ESI): m/z calculated for C31H43N5O2 + H
+ [M 








(pyrrolidin-1-yl)propoxy)-3H-benzo[e][1,4]diazepin-5-amine 22b (EML741) 
 
Method A. Compound 22b was obtained as a yellow solid (<5%) from 
derivative 21b according to the procedure described for 22a. 
Method B. A 10 mL CEM pressure vessel equipped with a stirrer bar was 
charged with compound 21b (60 mg, 0.140 mmol), 4-amino-1-isopropyl piperidine 
(222 µL) and acetic acid (161 µL). The microwave vial was sealed and heated in a 
CEM Discover microwave synthesizer to 120 °C (measured by the vertically 
focused IR temperature sensor) for 60 min. The crude material is diluted with a 
mixture ACN/H2O in 2:8 ratio and purified by reverse phase high–performance 
liquid chromatography (RP-HPLC) to afford the 3 × TFA salt of 22b (37 mg, 30%). 
1H NMR (400 MHz, D2O) δ 7.44 (s, 2H), 4.37 (t, J = 5.7 Hz, 2H), 4.20 – 4.11 (m, 
1H), 4.05 (s, 3H), 3.85 – 3.74 (m, 2H), 3.64 – 3.54 (m, 3H), 3.50 (t, J = 7.5 Hz, 2H), 
3.28 – 3.09 (m, 5H), 2.43 – 2.30 (m, 4H), 2.27 – 2.17 (m, 2H), 2.13 – 1.93 (m, 8H), 
1.89 – 1.65 (m, 4H), 1.61 – 1.38 (m, 4H), 1.39 – 1.32 (m, 6H); 13C NMR (100 MHz, 
D2O the signal of TFA was not included) δ 151.80, 149.34, 147.90, 145.65, 132.11, 
115.57, 101.58, 100.23, 66.70, 58.40, 56.18, 54.35, 52.71, 50.59, 47.77, 38.52, 
30.54, 29.85, 25.75, 25.04, 24.95, 22.64, 16.08; HRMS (ESI): m/z calculated for 
C31H49N5O2 + H
+ [M + H+]: 524.3959. Found: 524.3972. 
 






To a solution of 18a (600 mg, 2.13 mmol) in THF/MeOH (60 mL; 1:1 ratio) 
cooled at 0 °C, NaBH4 was added portion-wise until disappearance of the starting 
material (TLC silica gel). The reaction mixture was evaporated, taken up with water 
(40 mL), and extracted with CHCl3 (3 × 30 mL). The organic phase was dried and 






Synthesized in 90% yield starting from compound 18b following the 
procedure described for 15a. Characterization, see Paragraph 7.1.2. 
 






Compound 23a was obtained as a pale yellow solid (77%) from derivative 
15a according to the procedure described for 19a. 1H NMR (400 MHz, DMSO-d6) 
δ 7.71 (t, J = 5.8 Hz, 1H exchangeable with D2O), 7.39 – 7.23 (m, 5H), 7.19 (s, 1H), 
6.53 (s, 1H), 6.23 (d, J = 3.8 Hz, 1H, exchangeable with D2O), 4.73 – 4.60 (m, 1H), 
4.09 – 3.99 (m, 2H), 3.79 (t, J = 6.4 Hz, 2H), 3.68 (s, 3H), 3.43 – 3.34 (m, 2H), 2.24 





Compound 23b was obtained as a white solid (67%) from derivative 15b 
according to the procedure described for 19a. 1H NMR (400 MHz, DMSO-d6) δ 
7.76 (t, J = 5.3 Hz, 1H exchangeable with D2O), 7.19 (s, 1H), 6.44 (s, 1H), 6.00 (d, 
J = 4.5 Hz, 1H exchangeable with D2O), 4.01 (t, J = 6.2 Hz, 2H), 3.78 (t, J = 6.4 
Hz, 2H), 3.64 (s, 3H), 3.27 – 3.11 (m, 2H), 3.10 – 3.02 (m, 1H), 2.25 – 2.13 (m, 
2H), 1.89 – 1.55 (m, 5H), 1.50 – 1.36 (m, 1H), 1.27 – 0.83 (m, 5H); MS: m/z (%) 
367 (100) [M + H+]; 369 (32) [M + H + 2+]. 






 To a suspension of compound 23a (100 mg, 0.28 mmol) in anhydrous toluene 
(5 mL), Lawesson’s reagent (168 mg, 0.42 mmol) was added. The reaction mixture 
was heated at 85 °C for 1 h. After cooling at room temperature, potassium carbonate 
(69 mg, 0.50 mmol) and iodoethane (446 µL) were added and the reaction mixture 
was heated again to 85 °C for 2 h. The solvent was evaporated and the residue was 
was partitioned between H2O (5 mL) and EtOAc (10 mL). The organic layer was 
washed with water (2 × 5 mL), 10% Na2S2O3 solution (3 × 5 mL) and brine (10 
mL), dried over sodium sulfate, filtered and concentrated in vacuo. The residue was 
purified by silica gel chromatography (CH2Cl2/MeOH) to give the desired product 
24a (86 mg) in 77% yield as yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 7.43 – 
7.18 (m, 5H), 7.00 (s, 1H), 6.64 (s, 1H), 6.02 (br s, 1H exchangeable with D2O), 
5.01 – 4.88 (m, 1H), 4.13 – 3.99 (m, 2H), 3.92 – 3.59 (m, 7H), 2.99 – 2.79 (m, 2H), 
2.30 – 2.11 (m, 2H), 1.15 (t, J = 7.3 Hz, 3H). MS: m/z (%) 405 (100) [M + H+]; 407 










Compound 24b was obtained as yellow solid (72%) from derivative 23b 
according to the procedure described for 24a.1H NMR (400 MHz, DMSO-d6) δ 6.97 
(s, 1H), 6.55 (s, 1H), 5.84 (br s, 1H exchangeable with D2O), 4.02 (t, J = 6.1 Hz, 
2H), 3.78 (t, J = 6.3 Hz, 2H), 3.69 – 3.55 (m, 5H), 3.05 – 2.79 (m, 2H), 2.30 – 2.11 
(m, 2H), 1.98 – 1.52 (m, 5H), 1.44 – 0.91 (m, 9H); MS: m/z (%) 411 (100) [M + 





Synthesized in 65% yield starting from compound 24a following the 
procedure described for 25a. Yellow oil. 1H NMR (400 MHz, DMSO-d6) δ 7.43 – 
7.18 (m, 5H), 6.98 (s, 1H), 6.60 (s, 1H), 5.87 (d, J = 2.6 Hz, 1H exchangeable with 
D2O), 4.93 – 4.85 (m, 1H), 4.08 – 3.89 (m, 2H), 3.86 – 3.72 (m, 4H), 3.69 (s, 3H), 
2.97 – 2.78 (m, 2H), 2.46 – 2.38 (m, 4H), 1.98 – 1.83 (m, 2H), 1.71 – 1.64 (m, 4H), 
1.14 (t, J = 7.3 Hz, 3H); MS: m/z 440 [M + H+]. 
 






Synthesized in 67% yield starting from compound 24b following the 
procedure described for 25a. Yellow oil. 1H NMR (400 MHz, DMSO-d6) δ 6.94 (s, 
1H), 6.51 (s, 1H), 5.67 (d, J = 3.3 Hz, 1H exchangeable with D2O), 3.93 (t, J = 6.7 
Hz, 2H), 3.78 – 3.53 (m, 5H), 3.42 – 3.35 (m, 2H), 3.27 – 3.19 (m, 1H), 3.02 – 2.77 
(m, 2H), 2.45 – 2.34 (m, 4H), 2.05 – 1.56 (m, 11H), 1.40 – 0.81 (m, 9H). MS: m/z 






Compound 26a (3 × TFA salt) was obtained as a yellow solid (31%) from 
derivative 25a according to the procedure described for 22a. 1H NMR (400 MHz, 
D2O) δ 7.50 – 7.33 (m, 5H), 7.10 (s, 1H), 6.64 (s, 1H), 5.14 – 5.06 (m, 1H), 4.23 (t, 
J = 5.0 Hz, 2H), 3.92 – 3.87 (m, 3H), 3.83 – 3.73 (m, 5H), 3.67 – 3.51 (m, 3H), 3.46 
(t, J = 7.6 Hz, 2H), 3.22 – 2.99 (m, 4H), 2.47 – 2.38 (m, 1H), 2.31 (h, J = 5.9 Hz, 
2H), 2.26 – 2.12 (m, 2H), 2.13 – 1.96 (m, 4H), 1.93 – 1.76 (m, 1H), 1.35 (d, J = 6.7 
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Hz, 6H); 13C NMR (100 MHz, D2O the signal of TFA was not included) δ 163.44, 
153.50, 143.35, 142.78, 141.32, 128.96, 128.26, 126.52, 112.82, 105.89, 104.74, 
66.29, 66.11, 58.59, 56.42, 54.34, 52.68, 47.40, 47.36, 47.12, 46.69, 28.11, 28.01, 
25.04, 22.63, 16.07; HRMS (ESI): m/z calculated for C31H45N5O2 + H
+ [M + H+]: 






Compound 26b (3 × TFA salt) was obtained as a yellow solid (30%) from 
derivative 25b according to the procedure described for 22a; 1H NMR (400 MHz, 
D2O) δ 7.21 (s, 1H), 7.00 (s, 1H), 4.26 (t, J = 5.2 Hz, 2H), 4.06 – 3.95 (m, 1H), 3.91 
(s, 3H), 3.85 – 3.70 (m, 3H), 3.69 – 3.50 (m, 5H), 3.44 (t, J = 7.6 Hz, 2H), 3.28 – 
3.06 (m, 4H), 2.45 (t, J = 12.3 Hz, 2H), 2.30 (q, J = 6.6, 6.1 Hz, 2H), 2.18 (q, J = 
7.5, 7.0 Hz, 2H), 2.09 – 1.92 (m, 4H), 1.91 – 1.61 (m, 6H), 1.41 – 1.35 (m, 6H), 
1.31 – 1.01 (m, 5H); 13C NMR (100 MHz, D2O the signal of TFA was not included) 
δ 162.53, 152.90, 146.47, 134.88, 112.72, 111.43, 107.29, 70.38, 66.67, 58.65, 
56.39, 54.32, 52.62, 47.81, 47.27, 47.22, 41.92, 39.38, 28.87, 28.49, 28.10, 28.04, 
25.53, 25.37, 25.01, 22.62, 16.06; HRMS (ESI): m/z calculated for C31H51N5O2 + 
H+ [M + H+]: 526.4116. Found: 526.41115. 
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7.1.4 Procedures for the preparation of 4-azidoquinoline 27 
Synthesis of 1-(4-(benzyloxy)-3-methoxyphenyl)ethan-1-one (30) 
 
To a solution of acetovanillone (5.0 g, 30.1 mmol) in acetone (90 mL) K2CO3 
(6.2 g, 45.1 mmol) and benzyl bromide (5.7 g, 33.1 mmol) were added. The reaction 
mixture was refluxed for 2 h, then cooled to room temperature and concentrated in 
vacuo. The residue was taken up with EtOAc (150 mL) and washed with water (3 
× 50 mL) and brine (75 mL), dried over Na2SO4, filtered, and concentrated to afford 
the desired product (30) as white solid (7.5 g, 97%); Known compound. NMR data 
are consistent with those reported.1H NMR (400 MHz, Chloroform-d) δ 7.53 – 7.29 
(m, 7H), 6.87 (d, J = 8.4 Hz, 1H), 5.20 (s, 2H), 3.91 (s, 3H), 2.52 (s, 3H);177 MS: 
m/z 257 [M + H+]. 
 
Synthesis of 1-(4-(benzyloxy)-5-methoxy-2-nitrophenyl)ethan-1-one (31) 
 
To an ice-cooled solution of compound 30 (3.00 g,11.7 mmol) in acetic 
anhydride (60 mL), fuming nitric acid (1.6 mL, 35.1 mmol) was added. The reaction 
mixture was stirred at 0 °C for 15 min, then it was poured into ice-water and 
extracted with CH2CH2 (3 × 50 mL). The combined organic layers were washed 
with NaHCO3 saturated solution (3 × 50 mL) and brine, dried, and concentrated in 
vacuo. The product was recovered as yellow solid (2.94 g, 83%). 1H NMR (400 
MHz, DMSO-d6) δ 7.76 (s, 1H), 7.50 – 7.33 (m, 5H), 7.25 (s, 1H), 5.25 (s, 2H), 
3.93 (s, 3H), 2.52 (s, 3H). MS: m/z 302 [M + H+]. 
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Synthesis of 1-(2-amino-4-(benzyloxy)-5-methoxyphenyl)ethan-1-one (32) 
 
1-(4-(benzyloxy)-5-methoxy-2-nitrophenyl)ethan-1-one 31 (0.51 g, 1.69 
mmol), iron powder (0.47 g, 8.46 mmol) and ammonium chloride (0.05 g, 0.85 
mmol) were added to a mixture EtOH/H2O (12 mL; 2:1 ratio). The mixture was 
stirred at reflux for 30 min, then cooled and filtered through a pad of Celite. The 
solvents were removed under reduced pressure and the residue was taken up with 
EtOAc (30 mL) and washed with H2O (2 × 15 mL) and brine, dried over Na2SO4, 
filtered and evaporated to give a residue that was purified by flash chromatography 
(n-Hex/EtOAc) to yield the desired compound as a yellow solid (4.00 g, 87%). 
Known compound. NMR data are consistent with those reported. 1H NMR (400 
MHz, DMSO-d6) δ 7.50 – 7.29 (m, 5H), 7.15 (s, 1H), 7.07 (br s, 2H exchangeable 
with D2O), 6.41 (s, 1H), 5.07 (s, 2H), 3.71 (s, 3H), 2.43 (s, 3H);
178 MS: m/z 272 [M 
+ H+]. 
 
Synthesis of N-(2-acetyl-5-(benzyloxy)-4-methoxyphenyl) 
cyclohexanecarboxamide (33) 
 
A solution of compound 32 (1.11 g, 4.09 mmol) and DIPEA (1.43 mL, 8.18 
mL) in anhydrous THF (30 mL) was cooled in ice bath, then cyclohexanecarbonyl 
chloride (0.66 g, 4.50 mmol) was added. The reaction mixture was allowed to warm 
to room temperature and was stirred for 90 min. The solvent was removed under 
reduced pressure and the residue was taken up with EtOAc (50 mL) and washed 
with H2O (2 × 20 mL) and brine, dried over Na2SO4, filtered and evaporated, 
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affording the title compound as yellow solid (1.53 g, 98%); 1H NMR (400 MHz, 
DMSO-d6) δ 11.79 (s, 1H exchangeable with D2O), 8.47 (s, 1H), 7.54 – 7.28 (m, 
6H), 5.14 (s, 2H), 3.83 (s, 3H), 2.63 (s, 3H), 2.37 – 2.22 (m, 1H), 2.05 – 1.55 (m, 
5H), 1.51 – 1.12 (m, 5H). MS: m/z 382 [M + H+]. 
 
Synthesis of 7-(benzyloxy)-2-cyclohexyl-6-methoxyquinolin-4-ol (34) 
 
A mixture of derivative 33 (1.69 g, 4.43 mmol) and NaOH (1.77 g, 44.30 
mmol) in 1,4-dioxane (150 mL) was refluxed for 24 h. The reaction mixture was 
concentrated in vacuo then ice-water was added and the precipitate was collected 
via filtration over a Büchner funnel. Yellow solid (1.12 g, 80%); 1H NMR (400 
MHz, DMSO-d6) δ 11.18 (br s, 1H exchangeable with D2O), 7.56 – 7.30 (m, 6H), 
7.10 (s, 1H), 5.82 (s, 1H), 5.18 (s, 2H), 3.82 (s, 3H), 2.47 – 2.41 (m, 1H), 1.94 – 
1.63 (m, 5H), 1.55 – 1.13 (m, 5H); MS: m/z 364 [M + H+]. 
 
Synthesis of 4-azido-7-(benzyloxy)-2-cyclohexyl-6-methoxyquinoline (27) 
 
7-(benzyloxy)-2-cyclohexyl-6-methoxyquinolin-4-ol 34 (1.00 g, 2.75 mmol) 
was suspended in anhydrous DMF (15 mL), then triethylamine (0.50 mL, 3.58 
mmol) and diphenyl phosphoryl azide (0.65 mL, 3.03 mmol) were added. The 
mixture was heated to 100 °C and stirred for 1 h, then it was cooled to room 
temperature, diluted with H2O (60 mL) and extracted with EtOAc (3 × 60 mL). The 
combined organic extracts were washed with NaHCO3 saturated solution (3 × 50 
Materials and Methods   
106 
 
mL) and brine, dried, and concentrated in vacuo. The residue was purified by silica 
gel chromatography (n-Hex/EtOAc) to give the title compound (0.73 g) in 73% 
yield as pale yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 7.52 – 7.47 (m, 2H), 
7.46 – 7.33 (m, 4H), 7.22 – 7.15 (m, 2H), 5.28 (s, 2H), 3.89 (s, 3H), 2.80 (t, J = 11.9 
Hz, 1H), 2.00 – 1.14 (m, 10H); MS: m/z 389 [M + H+]. 
 
7.2 AlphaLISA assays protocols 
General directions. All the assays were performed in white Optiplate-384 
(PerkinElmer, # 6007299) at room temperature in a final volume of 25 µL. Signals 
were read in Alpha mode with the EnSight Multimode Plate Reader (PerkinElmer). 
All incubation steps with AlphaLISA beads were performed at room temperature 
under subdued lighting condition. 
G9a  
The assays were performed using the following Assay Buffer: 50 mM Tris-
HCl, pH 9.0, 50 mM NaCl, 1 mM DTT, 0.01% Tween-20. Human recombinant 
G9a (BPS Bioscience, # 51001) (0.1 nM, final concentration) was diluted in Assay 
Buffer, then and proper inhibitor (0.1% DMSO, final concentration) was added. 
After a pre-incubation time of 15 minutes, Histone H3 (1-21) peptide, biotinylated 
(AnaSpec, # 61702) (100 nM, final concentration) and SAM (Sigma, # A7007) (15 
μM, final concentration) were added. The reaction was incubated for 30 min, 
afterwards the Anti-methyl-Histone H3 Lysine 9 (H3K9me2) AlphaLISA Acceptor 
Beads (PerkinElmer, # AL117) in Epigenetic Buffer 1X were added in each well 
(20 μg/mL, final concentration). After an incubation of 1 h, Streptavidin Donor 
beads (PerkinElmer, # 6760002) were diluted in Epigenetic Buffer 1X and added 
in each well (20 μg/mL, final concentration). The Alpha signal was read after 30 
minutes of incubation. 
To determine the inhibition pattern of EML741, were performed two 
different set of experiments. In the first set, SAM concentration was varied from 
3.75 to 30 µM, while holding H3 biotinylated peptide constant (100 nM). In the 
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second one, using fixed SAM concentration (15 µM), the concentration of the H3 
biotinylated peptide was varied from 25 to 100 nM. 
 
PRMT1 
The assays were performed using the following Assay Buffer: 30 mM Tris-
HCl, pH 8.0, 1 mM DTT, 0.01% BSA, 0.01% Tween-20. Human recombinant 
PRMT1 (BPS BioScience, # 51041) (0.87 nM, final concentration) was diluted in 
Assay Buffer, then and proper inhibitor (0.1% DMSO, final concentration) was 
added. After a pre-incubation time of 15 minutes, Histone H4 (1-21) peptide, 
biotinylated (AnaSpec, # 62555) (100 nM, final concentration) and SAM (Sigma # 
A7007) (2 μM, final concentration) were added. The reaction was incubated for 1 
h, afterwards the Anti-methyl-Histone H4 Arginine 3 (H4R3me) AlphaLISA 
Acceptor Beads (PerkinElmer, # AL150) in Epigenetic Buffer 1X were added in 
each well, to reach a final concentration of 20 μg/mL. After an incubation of 1 h, 
Streptavidin Donor beads (PerkinElmer, # 6760002) were diluted in Epigenetic 
Buffer 1X and added in each well (20 μg/mL, final concentration). The Alpha signal 
was read after 30 minutes of incubation. 
 
PRMT3 
The assays were performed using the following Assay Buffer: 30 mM Tris-
HCl, pH 8.0, 1 mM DTT, 0.01% BSA, 0.01% Tween-20. Human recombinant 
PRMT3 (BPS BioScience, # 51043) (2 ng/ μL, final concentration) was diluted in 
Assay Buffer, then and proper inhibitor (0.1% DMSO, final concentration) was 
added. After a pre-incubation time of 15 minutes, Histone H4 (1-21) peptide, 
biotinylated (AnaSpec, # 62555) (50 nM, final concentration) and SAM (Sigma, # 
A7007) (10 μM, final concentration) were added. The reaction was incubated for 1 
h, afterwards the Anti-methyl-Histone H4 Arginine 3 (H4R3me) AlphaLISA 
Acceptor Beads (PerkinElmer, # AL150) in Epigenetic Buffer 1X were added in 
each well, to reach a final concentration of 20 μg/mL. After an incubation of 1 h, 
Streptavidin Donor beads (PerkinElmer, # 6760002) were diluted in Epigenetic 
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Buffer 1X and added in each well to reach a final concentration of 20 μg/mL. The 
Alpha signal was read after 30 minutes of incubation. 
 
SETD8 
The assays were performed using the following Assay Buffer: TrisHCl 50 
mM pH 8.5, NaCl 50 mM, MgCl2 5 mM, DTT 1 mM, BSA 0.01%. GST-SETD8 
(expressed in house) (1 μM, final concentration) was diluted in Assay Buffer, then 
and proper inhibitor (0.1% DMSO, final concentration) was added. After a pre-
incubation time of 15 minutes, Histone H4 (Active Motif, # 31223), (150 nM, final 
concentration) and SAM (Sigma, # A7007) (200 μM, final concentration) were 
added. The reaction was incubated for 1 h, afterwards it was stopped by adding 5 
μL of High Salt Buffer (50 mM Tris-HCl pH 7.4, 0.1% Tween-20, 1 M NaCl, 0.3% 
poly-L-lysine). After an incubation of 15 min, a mixture of anti-Histone H4K20me1 
Acceptor beads (PerkinElmer, # AL145) and biotinylated anti-H4 antibody 
(PerkinElmer, # AL146) was prepared in Epigenetic Buffer 1X and added in each 
well, to reach a final concentration of 20 μg/mL and 1 nM respectively. After an 
incubation of 1 h, Streptavidin Donor beads (PerkinElmer, # 6760002) were diluted 
in Epigenetic Buffer 1X and added in each well (20 μg/mL, final concentration). 
The Alpha signal was read after 30 minutes of incubation. 
 
KDM4A 
The assays were performed using the following Assay Buffer: 50 mM Hepes 
pH 7.5, 0.01% Tween-20, 0.1% BSA. hKDM4A (BPS BioScience, # 50103) (100 
nM, final concentration) was diluted in Assay Buffer, then a mixture of Fe(II) 
(Sigma # 215406) (5 μM, final concentration), ascorbate (Sigma, # 11140) (100 
μM, final concentration) and proper inhibitor (0.1% DMSO, final concentration) 
was added. After a pre-incubation time of 15 minutes, Histone H3 (1 - 21) lysine 9 
tri-methylated peptide, biotinylated (H3K9me3) (AnaSpec, # 64360) (200 nM, final 
concentration) and 2OG (Sigma, # K2000) (5 μM, final concentration) were added. 
The reaction was incubated for 1 h, afterwards the Anti-methyl-Histone H3 Lysine 
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9 (H3K9me2) AlphaLISA Acceptor beads (PerkinElmer, # AL117) in Epigenetic 
Buffer 1X were added in each well, to reach a final concentration of 20 μg/mL. 
After an incubation of 1 h, Streptavidin Donor beads (PerkinElmer, # 6760002) 
were diluted in Epigenetic Buffer 1X and added in each well to reach a final 




The assays were performed using the following Assay Buffer: 50 mM Tris-
HCl, pH 8.0, 0.1 mM EDTA, 1 mM DTT, 0.01% Tween-20, 0.01% BSA, 330 nM 
TSA. Human recombinant p300 (Enzo LifeScience, # BML-SE451) (5 nM, final 
concentration) was diluted in Assay Buffer, then and proper inhibitor (0.1% DMSO, 
final concentration) was added. After a pre-incubation time of 15 minutes, Histone 
H3 (1-21) peptide, biotinylated (Anaspec # 61702) (50 nM, final concentration) and 
Acetyl CoA (Sigma, # A2056) (3 μM, final concentration) were added. After an 
incubation of 30 min, reactions were stopped by adding garcinol (Sigma, # G5173) 
(61.6 μM, final concentration) and Anti-acetyl histone H3 lysine 9 (H3K9Ac) 
acceptor beads (PerkinElmer, # AL114) in Epigenetic Buffer 1X was added in each 
well, to reach a final concentration of 20 μg/mL. After an incubation of 1 h, 
Streptavidin Donor beads (PerkinElmer, # 6760002) were diluted in Epigenetic 
Buffer 1X and added in each well (20 μg/mL, final concentration). The Alpha signal 
was read after 30 minutes of incubation. 
 
7.3 EML741 Stability assay 
Compound EML741 was dissolved in PBS to reach a final concentration of 
100 μM. 5 μL aliquots of the prepared solution were analyzed by HPLC at time 0 
(soon after the preparation) and after 12, 24, 48 and 72 h. Spectra were recorded on 
a Shimadzu SPD 20A UV/vis detector (λ = 220 nm) using C-18 column 
Phenomenex Synergi Fusion RP 80A (75mm × 4.60 mm; 4 μm) at 25 °C using a 
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mobile phase A (water + 0.1% TFA) and B (ACN + 0.1% TFA) at a flow rate of 1 
mL/min. 
7.4 PAMPA, general protocol 
Test compounds were dissolved in DMSO and for each sample, donor 
solution (500 μM) was prepared by diluting 1 mM DMSO stock solution using 
phosphate buffer (pH 7.4, 0.01 M). In the donor plate (96-well polycarbonate-based 
filter plate), filters were covered with 5 μL of a 1% (w/v) dodecane solution of L-
α-phosphatidylcholine for PAMPA or 2% (w/v) of BBB-specific lipid solution 
(Avanti Lipids Polar, 141101P) for PAMPA-BBB. Donor solution (150 μL) was 
added to each well. The acceptor plate wells were filled with 300 μL of solution 
(50% DMSO in phosphate buffer). The sandwich was incubated for 24 h at room 
temperature under gentle shaking. Then, the sandwich plates were separated and 
250 μL of the acceptor plate were transferred to a UV quartz microtiter plate and 
measured by UV spectroscopy, using a Multiskan GO microplate 
spectrophotometer (Thermo Scientific) at 250-500 nm (steps of 5 nm). Reference 
solutions (250 μL) were prepared diluting the sample stock solutions to the same 
concentration as that with no membrane barrier. The apparent permeability value 
Papp is determined from the ratio r of the absorbance of compound found in the 
acceptor chamber divided by the theoretical equilibrium absorbance (determined 




(𝑉𝐷 + 𝑉𝑅) ∗ 𝐴𝑡
) ∗ ln⁡(1 − 𝑟) 
 
In this equation, VR is the volume of the acceptor compartment (0.3 cm3), 
VD is the donor volume (0.15 cm3), A is the accessible filter area (0.24 cm2), and t 
is the incubation time in seconds. All the compounds were tested in triplicate. 
 
  Materials and Methods 
111 
 
7.5 Cell culture and transfection 
The human chronic myelogenous leukemia cell line KBM7 was cultured in 
Iscove’s modified Dulbecco’s medium (IMDM, Gibco), supplemented with 10% 
fetal bovine serum (FBS; Gibco) and 100 units/ml streptomycin and penicillin (both 
from Gibco). The human embryonic kidney HEK293T and breast cancer MCF7 cell 
lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gibco) 
supplemented with 10% of fetal bovine serum (FBS, Gibco) and 100 units/mL 
streptomycin and penicillin. All cell lines were incubated in a 5% CO2 atmosphere 
at 37 °C. 
HEK293T cells were transfected with Lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s instructions. The plasmids used (pLV-Azurite 
(Addgene, #36086), psPAX2 (Addgene, #12259) and pCMV-VSV-G (Addgene, 
#8454)) were purified from cultured transformed bacteria using a Plasmid 
Maxiprep Purification Kit (Qiagen) following to the manufacturer’s protocol. 
 
7.6 Western blot 
KBM7 (8 mL, 2.5 × 105 cells/mL) were seeded and incubated with UNC0638 
at different concentrations for the specified time and conditions. MCF7 (10 mL, 3.5 
× 104 cells/mL) were seeded, allowed to attach overnight and subsequently treated 
with the indicated compounds for the specified time and concentrations. An equal 
amount of DMSO (0.5 %) was used to treat the control samples. After the treatment, 
the cells were harvested and washed three times with 1X PBS (Phosphate Buffered 
Saline, Gibco) and then resuspended in Tryton extraction buffer (PBS containing 
0.5% Triton × 100 (v/v), 2mM phenylmethylsulfonyl fluoride (PMSF), 0.02% (w/v) 
NaN3) supplemented with a protease inhibitor cocktail Sigma-Aldrich # 
11873580001). All subsequent manipulations were performed at 4 °C. After 
incubation for 30 min on a rotator, nuclei were collected by centrifugation for 10 
min at 500 rcf. The nuclear pellets were suspended in 0.2 N HCl solution and 
incubated overnight on a rotator. After centrifugation for 10 min at 500 rcf, histones 
containing supernatant was collected. Protein concentrations were determined 
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using the Bradford assay. For each sample, equal amounts of proteins were 
separated on 15% polyacrylamide gels with SDS running buffer (50 mM Tris, 380 
mM glycine and 7 mM SDS) and transferred to nitrocellulose blotting membranes. 
All membranes were blocked with blocking buffer (5% (w/v) milk powder 
(BioRad) in TBST (Tris-buffered saline with Tween: 50 mM Tris (tris 
(hydroxymethyl)aminomethane), 150 mM NaCl, 0.05% (v/v) Tween 20, adjusted 
to pH 7.6)). Proteins were probed using the following antibodies: anti-H3K9me2 
(1:1000, Cell Signaling Technology, #4658), anti-histone H3 (1:1000, Cell 
Signaling Technology, #4499), anti-histone H4 (1:1000, Abcam, #ab7311) detected 
by HRP (horseradish peroxidase) conjugated donkey anti-rabbit IgG antibody 
(1:10000, Abcam, #ab16284) or donkey anti-mouse IgG antibody (Pierce) and 
visualized with the Pierce ECL Western Blotting substrate (Amersham), according 
to the provided protocol. 
 
7.7 Cell viability  
MTT Assay 
MCF7 (0.2 mL, 3.5 × 104 cells/mL) were seeded in 96-well microtiter plates 
(Corning), allowed to attach overnight and subsequently treated with the indicated 
compounds for the specified conditions. Control samples were treated with an equal 
amount of DMSO (0.5 %). After the specified incubation time, 10 μL of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma-Aldrich # 
M2128) solution (5.0 mg/mL) was added to each well, and incubation continued 
for an additional 2 hours. Formed blue formazan crystals were dissolved by adding 
100 μL of DMSO. The absorbance was read in a Multiskan GO microplate 




KBM7 (0.1 mL, 2.5 × 105 cells/mL) were seeded in 96-well microtiter plates 
(Corning) and incubated with UNC0638 at different concentrations, an equal 
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amount of DMSO was used as control (0.5% final). After 24 or 48 h CellTiter-Glo® 
Reagent (Promega) was added and the plates were incubated in the dark for 30 
minutes. The luminescent signal was read with EnVision 2105 Multimode Plate 
Reader (PerkinElmer). 
 
 7.8 Cell sorting 
Cell sorting was performed using the FACSAria (BD Biosciences) sorter. 
Briefly, BFP-infected cells were sorted in presence of 2 µM UNC0638, 48 h after 
the infection. Wild type KMB7 as negative control. BFP-positive cells (6.3%, very 
positive) were seeded in fresh medium, without UNC0638. After five days from the 
first sorting, cells were sorted again, in absence of UNC0638, selecting the negative 
population (6.7%, very negative). These steps were repeated two times. Clones 
were isolated by single cell sorting in the last passage.  
 
7.9 Screening  
 KBM7 were seeded on clear flat-bottom 384-well plates (Corning) and 
treated with the compounds in single dose (primary screening) or dose response (hit 
validation). DMSO was used as negative control. After 24 h, live-cell imaging 
pictures were taken with the Operetta High Content Screening System 
(PerkinElmer), 20x objective and nonconfocal mode and analyzed using the 
Harmony software (PerkinElmer) for nuclei detection and analysis, adapted for the 
nucleus diameter range of KBM7 (13 μM).  
 
7.10 Quantitative PCR (qPCR)  
1704001-A7 cells (4.0 × 105 cells/mL) were seeded and incubated with the 
indicated compounds for 24 h. the cells were harvested and washed three times with 
ice cold-1X PBS (Gibco). RNA was extracted with RNeasy Mini Kit (Quiagen), 
following the recommended protocol. RNA was quantified and evaluated for purity 
(NanoDrop, Thermo Fisher Scientific).  
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1 µg of each sample was converted to cDNA with High Capacity cDNA 
Reverse Transcription (RT) Kit (Applied Biosystems) following the standard 
protocol. RT was performed in a thermal cycler (SimpliAmp Thermal Cycler, 
Thermo Fisher Scientific) programmed for 25 °C (10 min), 37 °C (120 min), 85 °C 
(5 min), then 4 °C (∞). 
qPCR was performed using the Power SYBR Green Master mix (Invitrogen) 
as described in the manufacture’s protocol. qPCR was conducted at 95 °C for 10 min, 
followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min (ramp rate: 4.8 °C/s; 
LightCycler 480 II, Roche). RT-PCR primers used: Azurite BFP (Sigma; forward 5′- 
CCTGAAGTTCATCTGCACCA, reverse 5′- GGTCTTGTAGTTGCCGTCGT); 
beta-2-microglobulin B2MG (Sigma; forward 5′- GAGGCTATCCAGCGTACTC, 
reverse 5′- CCAGACACATAGCAATTCAGG). 
Real-time amplification results were normalized to the endogenous 
housekeeping gene beta-2-microglobulin. The relative quantities were calculated 
using the comparative cycle threshold (ΔΔCT) method. 
 
7.11 NMR Data 
1H-NMR EML693, 3 × TFA salt  
13C-NMR EML693, 3 × TFA salt  
1H-NMR EML741, 3 × TFA salt  
13C-NMR EML741, 3 × TFA salt  
1H-NMR EML696, 3 × TFA salt  
13C-NMR EML696, 3 × TFA salt  
1H-NMR EML698, 3 × TFA salt  
13C-NMR EML698, 3 × TFA salt  
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